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Missense mutations in p53 are severely deleterious and occur in over 50% of all human
cancers. The majority of these mutations are located in the inherently unstable DNA-binding
domain (DBD), many of which destabilize the domain further and expose its aggregation-
prone hydrophobic core, prompting self-assembly of mutant p53 into inactive cytosolic
amyloid-like aggregates. Screening an oligopyridylamide library, previously shown to inhibit
amyloid formation associated with Alzheimer’s disease and type II diabetes, identified a
tripyridylamide, ADH-6, that abrogates self-assembly of the aggregation-nucleating sub-
domain of mutant p53 DBD. Moreover, ADH-6 targets and dissociates mutant p53 aggre-
gates in human cancer cells, which restores p53’s transcriptional activity, leading to cell cycle
arrest and apoptosis. Notably, ADH-6 treatment effectively shrinks xenografts harboring
mutant p53, while exhibiting no toxicity to healthy tissue, thereby substantially prolonging
survival. This study demonstrates the successful application of a bona fide small-molecule
amyloid inhibitor as a potent anticancer agent.
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Dubbed the “guardian of the genome”
1, p53 is a tumor
suppressor protein that is activated under cellular stresses,
including DNA damage, oncogene activation, oxidative
stress, or hypoxia2,3. Under normal conditions, p53 levels are kept
low by its negative regulator, the E3 ubiquitin ligase MDM2,
which targets p53 for proteasome-mediated degradation2,4. The
aforementioned cellular stresses disrupt the p53–MDM2 inter-
action, via phosphorylation of both proteins, and stimulate p53
acetylation, leading to its accumulation and activation4. Activated
p53 then triggers DNA damage repair, cell cycle arrest, senes-
cence, apoptosis, or autophagy, all of which are directed towards
the suppression of neoplastic transformation and inhibition of
tumor progression2,3,5.
p53 binds to several DNA sequences, functioning as a
sequence-specific transcriptional activator3,6. p53 is also char-
acterized by a high degree of structural flexibility, which facilitates
its interactions with a myriad of protein partners, allowing it to
exert its function as a master regulator of the cell6. Crucially, p53
missense mutations are found in over half of all human cancers,
making it the most mutated protein in cancer, and these muta-
tions are associated with some of the most pernicious manifes-
tations of the disease3,7. Thus, p53 has taken on a pivotal role in
the realm of cancer research and is considered a key target in the
development of cancer therapeutics4,7.
Under physiological conditions, p53 exists as a homotetramer,
with each monomer composed of globular DNA-binding and
tetramerization domains, connected by a flexible linker and
flanked by intrinsically disordered regions (a transactivation
domain followed by a proline-rich region at the N terminus, and
a C-terminal regulatory domain) (Fig. 1a)8. The DNA-binding
domain (DBD) consists of a central immunoglobulin-like
β-sandwich serving as a scaffold for the DNA-binding surface,
which is composed of a loop–sheet–helix motif and two large
loops that are stabilized by the tetrahedral coordination of a single
zinc ion (Fig. 1b)8. A majority (∼90%) of cancer-associated p53
mutations occur within the DBD, where they cluster into dis-
cernible “hotspots”9,10, resulting in the protein’s inactivation
through alterations in residues that are crucial for either DNA
interactions (contact mutants) or proper folding (structural
mutants), although it is now apparent that some mutations (such
as R248W) possess both characteristics6.
Several studies have reported that various p53 DBD mutants,
along with fragments of these proteins, form amyloid-like
aggregates in solution, cancer cell lines, and tumors11,12. p53
DBD is characterized by low thermodynamic and kinetic
stability8, and mutations in the domain often decrease its stability
further and prompt its unfolding, which leads to exposure of its
hydrophobic core13,14. Furthermore, many of the DBD muta-
tions, including the commonly occurring R248W/Q, R273C/H,
and R175H10, involve replacing the cationic arginine, a so-called
“gate-keeper” amino acid that prevents protein aggregation via
the repulsive effect of its charge15, with residues (tryptophan,
glutamine, cysteine, or histidine) that have a high aggregation/
amyloidogenic potential15,16. Thus, these DBD mutations serve to
not only expose the hydrophobic core of the domain, but also to
enhance its aggregation propensity. This prompts self-assembly of
mutant p53 into amyloid-like aggregates within inactive cellular
inclusions that incorporate the wild-type (WT) isoform, thereby
blocking the protein’s tumor suppressor function17.
Increasing evidence implicates aggregation of mutant p53 (e.g.
R248Q, R248W, and R175H) in the associated oncogenic gain-of-
function (GoF), i.e. the acquisition of activities that promote
tumor growth, metastasis and chemoresistance11,12,18. For
instance, co-sequestration of mutant and WT p53 into inactive
cellular inclusions may result in overexpression of antiapoptotic
and pro-proliferative genes previously repressed by p53 (refs. 3,5).
Aggregation of mutant p53 also induces misfolding of the p53
paralogs p63 and p73, which are then incorporated into the
inclusions, facilitated by interactions of the aggregation-prone
core of p53 DBD with near identical segments present in the p63
and p73 DBDs17. p63 and p73, which are rarely mutated in
tumors, have partial functional overlap with p53 (refs. 6). How-
ever, coaggregation with mutant p53 suppresses the regulatory
functions of p63 and p73, resulting in deficient transcription of
target genes involved in cell growth control, and apoptosis, which
leads to uncontrolled proliferation, invasion, and metastasis17.
Additionally, aggregation of mutant p53 has been shown to
induce overexpression of heat-shock proteins, in particular Hsp70
(ref. 17), that promote tumor cell proliferation and inhibit
apoptosis19. Thus, amyloid-like aggregation of mutant p53 may
contribute to both its loss of tumor suppressor function and its
oncogenic GoF.
Of relevance, replacing a hydrophobic amino acid in the
aggregation-prone core of p53 DBD with the “gate-keeper”
arginine residue (I254R) abrogates coaggregation of mutant p53
with the WT protein and its paralogs, p63 and p73, as well as
abolishes overexpression of Hsp70 (ref. 17). Notably, a p53 DBD-
derived peptide harboring the aggregation-suppressing I254R
mutation (denoted ReACp53; Fig. 1c) was shown to block mutant
p53 aggregation by masking the aggregation-prone core, which
restored the mutant protein to a WT p53-like functionality and
reduced cancer cell proliferation in vitro and halted tumor pro-
gression in vivo14. These studies indicate that targeting mutant
p53 aggregation is a viable and effective cancer therapeutic
strategy.
We previously reported the use of oligopyridylamide-based
α-helix mimetics to effectively modulate self-assembly of the
amyloid-β peptide (Aβ)20,21 and islet amyloid polypeptide
(IAPP)22,23, which are associated with Alzheimer’s disease (AD)
and type II diabetes (T2D), respectively. α-Helix mimetics are
small molecules that imitate the topography of the most com-
monly occurring protein secondary structure, serving as effective
antagonists of protein–protein interactions (PPIs) at the interac-
tion interface24,25. The appeal of α-helix mimetics stems from the
fact that their side-chain residues can be conveniently manipu-
lated to target specific disease-related PPIs24,25. In this study, we
explored whether such a protein mimetic-based approach can be
extended towards mutant p53 self-assembly. To that end, we asked
the following questions: (i) if intrinsically disordered mutant
p53 does indeed aggregate via an amyloid pathway, can the
oligopyridylamide-based α-helix mimetics effectively abolish this
process; (ii) if successful, does oligopyridylamide-mediated abro-
gation of mutant p53 aggregation lead to rescue of p53 function
and inhibition of cancer cell proliferation in vitro; and (iii) can this
oligopyridylamide-based strategy be applied to reverse tumor
growth in vivo without adversely affecting healthy tissue? In
addressing these questions, we establish the potential of using
functionalized amyloid inhibitors as mutant p53-targeted cancer
therapeutics.
Results
ADH-6 abrogates amyloid formation of the aggregation-
nucleating sequence of p53 DBD. We began with a reductionist
approach commonly adopted in the amyloid research field, namely
to target a short aggregation-prone segment within the protein
of interest26. Across most amyloid systems, aggregation can be
nucleated in a structure-specific manner by a small stretch of resi-
dues, which has a robust independent capacity for self-assembly26,27.
Aggregation prediction algorithms developed from biophysical stu-
dies of amyloids identified an aggregation-nucleating subdomain
(p53 residues 251–258) in the hydrophobic core of the p53 DBD
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Fig. 1 ADH-6 abrogates amyloid formation of aggregation-prone region of p53 DBD. a Schematic representation of the different domains of p53. The
DBD (residues 102–292) contains an aggregation-nucleating subdomain (residues 251–258) that is necessary and sufficient to drive p53
aggregation14,17,28. Another segment of interest comprises residues 213–217, which is the antigen recognized by the PAb 240 antibody that binds to
partially unfolded p53. Also highlighted in the DBD is R248, one of the most common mutation hotspots in p53 (IARC TP53 database; https://p53.iarc.fr)9.
b Structure of p53 DBD. Highlighted are the aggregation-nucleating subdomain (green) and the epitope recognized by PAb 240 (red). Both segments are
buried in the fully folded p53 structure. The 3D image was generated using PyMOL 2.3.5 (Schrödinger, New York, NY). c Primary sequences of the studied
WT and mutant R248W p53 DBD-derived peptides, denoted pWT and pR248W, respectively, which span residues 248–273. The peptides include the
aggregation-prone 252–258 sequence, as well as R248 and another of the most common mutation hotspots in p53 and R273 (IARC TP53 database;
https://p53.iarc.fr)9. d Chemical structures of the oligopyridylamides ADH-1 and ADH-6. e, f Effects of the oligopyridylamides on pR248W amyloid
formation. Kinetic profiles (left panel) and representative transmission electron microscopy (TEM) images (right panel) for aggregation of 25 μM pR248W
in the absence or presence of an equimolar amount of ADH-1 or ADH-6 co-mixed at the start of the reaction (e) or added during the growth phase (i.e. 5 h
after the start of the reaction) (f). Kinetic aggregation profiles were acquired by measuring the fluorescence of the thioflavin T (ThT) reporter (λex/em=
440/480 nm) at 5-min intervals at 37 °C (n= 4). TEM images were acquired at 10 h after the start of the aggregation reaction. Scale bar= 100 nm.
g Characterization of the binding interaction of the oligopyridylamides and pR248W measured using steady-state intrinsic tryptophan fluorescence
quenching. A 5 µM solution of pR248W was titrated with increasing concentrations of ADH-1 (left panel) or ADH-6 (right panel) and the tryptophan
fluorescence after each addition was normalized to account for the dilution (total dilution during the titration was <1%) and plotted against the ligand
concentration. The equilibrium dissociation constants (Kd) were then determined using a one-site-specific binding equation (Eq. 1). h Effects of the
oligopyridylamides on pR248W oligomerization monitored using the dot blot assay. Samples of 10 μM pR248W were incubated with or without an
equimolar amount of ADH-1 or ADH-6 for 0–24 h, and the presence of oligomers was detected using an amyloid oligomer-specific polyclonal antibody
(A11)35. i Effects of the oligopyridylamides on the self-assembly driven structural transition of pR248W. Time-dependent circular dichroism (CD) spectra
of 10 µM pR248W alone (left panel) or in the presence of an equimolar amount of ADH-1 (middle panel) or ADH-6 (right panel).
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that is necessary and sufficient to drive p53 aggregation14,17,28
(Fig. 1a, c). This segment forms a β-strand within the hydrophobic
core of the DBD (Fig. 1b). However, many of the mutations in the
p53 DBD destabilize its inherently unstable tertiary structure
further29 and increase exposure of the aggregation-nucleating sub-
domain which, in turn, promotes aggregation of the protein14,17.
Therefore, we chose to focus on p53251–258 but expanded the
sequence to include two of the most common mutation hotspots,
R248 and R273 (IARC TP53 database; https://p53.iarc.fr)9. Two
peptides were synthesized, one corresponding to residues 248–273 of
WT p53 DBD (peptide denoted pWT), the other composed of the
same sequence but harboring the R248Wmutation (peptide denoted
pR248W) (Fig. 1c). R248W is one of the most common p53 DBD
mutation that occurs in a range of malignancies, including pan-
creatic cancer9,10. Pancreatic cancer is an intractable malignancy that
often evades early diagnosis and resists treatment, and is conse-
quently associated with a very poor prognosis: it is the seventh most
common cause of death from cancer worldwide, with a five-year
survival rate of <5%30,31.
We tested the effects of 10 compounds (ADH-1–10), based on
the same oligopyridylamide molecular scaffold (Fig. 1d and
Supplementary Fig. 1a), on the aggregation of pR248W using the
thioflavin T (ThT)-based amyloid kinetic assay32. The com-
pounds were selected based on their distinct chemical fingerprints
and their ability to modulate amyloid assemblies20,21,23. The p53
DBD-derived peptides alone are characterized by a sigmoidal
ThT curve, which is indicative of a nucleation-dependent process
typical for amyloids (Supplementary Fig. 1b)33. Comparing the
two DBD-derived peptides, pR248W exhibited the greater
aggregation propensity, as evidenced by the shorter lag phase,
more rapid elongation phase and higher final ThT fluorescence
intensity. This is not surprising given that the mutation involves
replacing the cationic arginine, an aggregation “gate-keeper”
residue15 with the hydrophobic tryptophan, an aromatic residue
with the highest amyloidogenic potential of all 20 naturally
occurring amino acids16. Transmission electron microscopy
(TEM) imaging confirmed that the aggregation-prone segment
of mutant p53 DBD does indeed form fibrils (Fig. 1e, f).
The 10 oligopyridylamides varied in their antagonist activity
against pR248W aggregation. While the anionic ADH-1 did not
significantly affect pR248W’s self-assembly, the cationic ADH-6
completely inhibited the peptide’s amyloid formation, as
indicated by both the ThT assay and TEM imaging (Fig. 1e).
The determinants of efficacy of the oligopyridylamides appear to
be the number and positioning of cationic sidechains (Fig. 1d, e
and Supplementary Fig. 1a, b), suggesting that inhibition of
pR248W aggregation occurs through specific interactions invol-
ving the compounds’ cationic sidechains. A possibility is that the
oligopyridylamide–pR248W binding is stabilized by cation–π
interactions of a cationic sidechain of the protein mimetic and the
aromatic tryptophan residue of the mutant peptide34, which
provides a basis for strong binding and confers a degree of
specificity to the interaction. This is strongly supported by the
much higher binding affinity of ADH-6 (Kd= 366 ± 13 nM)
compared to ADH-1 (Kd= 15.4 ± 0.8 µM) for pR248W (Fig. 1g).
Similar cation–π interactions between the cationic sidechains of
ADH-6 and one or more of the several aromatic residues
(tyrosines and tryptophans) present in the DBD9 may facilitate
strong binding of the oligopyridylamide to full-length mutant
p53.
In order to restore WT p53-like activity in cancer cells
harboring aggregation-prone mutant p53, potential therapeutics
would need to dissociate pre-formed mutant p53 aggregates, as
well as prevent additional aggregation. Therefore, we tested the
capacity of ADH-6 to abrogate pre-formed pR248W aggregates.
Addition of ADH-6 to the mutant peptide at the mid-point of the
aggregation reaction, when a significant amount of fiber
formation had already taken place (Supplementary Fig. 1c),
resulted in a marked decrease in the ThT fluorescence intensity
and near complete absence of fibers in the TEM images at the end
of the reaction (Fig. 1f). The very few fibers that were detected
were much shorter and thinner than those observed for the
peptide alone (Fig. 1f and Supplementary Fig. 1d).
To further confirm the capacity of ADH-6 to prevent aggregation
of pR248W, we evaluated the effect of the oligopyridylamide on the
peptide’s oligomerization using a dot blot immunoassay (Fig. 1h).
pR248W was incubated with or without an equimolar amount of
ADH-6 or ADH-1 for 0–12 h and then detected using A11, an
antibody specific for amyloid oligomers, including those of mutant
p53 (refs. 35,36). The chemiluminescence signal intensity for samples
of pR248W alone increased from 0 to 6 h, indicating an increase in
the amount of soluble oligomers. Subsequently, the intensity
diminished significantly at 12 h due to conversion of the oligomers
into fibrils. Treatment with ADH-1 did not significantly change
the intensity of the dots, indicating that the oligopyridylamide did
not affect oligomerization of pR248W. In marked contrast, in the
presence of ADH-6 no formation of pR248W oligomers was
observed, as reflected by the weak intensity of the dots throughout
the time course of the experiment. Finally, we probed the effect of
ADH-6 on the secondary structure of pR248W using CD
spectroscopy (Fig. 1i). The peptide transitioned from a random
coil monomer to a β-sheet structure as it self-assembled into
amyloid fibers. pR248W underwent the same conformational
transition in the presence of an equimolar amount of ADH-1,
which is not surprising given its inability to inhibit the mutant
peptide’s oligomerization or amyloid formation (Fig. 1e, f, h). On
the other hand, in the presence of ADH-6 at an equimolar ratio,
pR248W remained in its native conformation for the duration of
the experiment, which confirms that ADH-6 potently inhibits self-
assembly of pR248W (Fig. 1e, f, h). Taken together, these results
demonstrate that ADH-6 not only strongly inhibits self-assembly of
the aggregation-prone segment of mutant p53 DBD, the oligopyr-
idylamide also effectively dissociates pre-formed aggregates of the
segment and prevents further aggregation.
Nuclear magnetic resonance (NMR) spectroscopy character-
ization of p53 DBD–ADH6 interaction interface. NMR spec-
troscopy was used to elucidate the p53 DBD–ADH-6 interactions.
Figure 2 shows the overlay of the heteronuclear single quantum
coherence (HSQC) maps, with and without oligopyridylamide,
for WT (Fig. 2a) and mutant R248W (Fig. 2b) p53 DBDs. Che-
mical shift perturbation (CSP) analysis was carried out to deter-
mine the protein–ligand interaction interface. The interaction
with ADH-6 also involved partially unfolded species that were
present in the samples of both DBD variants (Fig. 2a, b). Due to
this additional involvement, no quantitative estimate was reliably
feasible to assess a binding constant of ADH-6 to WT and
R248W p53 DBDs. A qualitatively equivalent pattern was
observed with either DBD variant (see Supplementary Section 2).
The increment of the CSP values with ligand concentration
(Fig. 2c) is the signature of a fast exchange regime, i.e. no stable
complex formation, without any major favorable or adverse
consequence of the hotspot mutation37 for ADH-6 affinity. This
result does not necessarily conflict with the nanomolar affinity of
ADH-6 for pR248W inferred from the fluorescence quenching
experiments (Fig. 1g) because p53 DBD presents numerous
interaction sites for ADH-6 (vide infra) beyond the aggregation-
nucleating subdomain. However, it is also possible that the
fast exchange regime observed by NMR may be, in part, a con-
sequence of the experimental conditions used to facilitate study of
the inherently unstable p53 DBDs37,38 (Supplementary Section 2).
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The backbone NH signals that exhibit the most significant CSP
values in both the considered p53 DBD variants appeared to
involve five clusters of residues that are highlighted with different
colors in Fig. 2d. The first cluster (highlighted in blue)
encompasses the area around the start of the C-terminal helical
fragment of the p53 DBD (helix 3, PDB:2fej38). The second
cluster (magenta) extends along strand 4 of sheet A and the
subsequent apical loop. The third cluster (green) is formed by a
sequential stretch of the apical loop preceding strand 1 of sheet A
along with the initial and final facing fragments of strands 3 and 4
in sheet B, respectively. The fourth cluster (orange) covers an
extended surface surrounding the start of helix 2. And the fifth,
and final, cluster (cyan) is assembled with contributions from
very distant residues, i.e. N-terminal and start and end of strands
6 and 7, respectively, of sheet B. Interestingly, cluster 1 includes
E271 and cluster 3 includes L257, L264, and R267, i.e. residues of
the p53248–273 segment we selected for our DBD-derived peptides,
pWT and pR248W (Fig. 1c), which has a high frequency of
mutations affecting p53 function14,37,38. In particular, L257 of
cluster 3 belongs to the aggregation-nucleating subdomain
(p53251–258) that promotes amyloid-like aggregation of mutant
p53 (refs. 14,37).
The conspicuous extension of the protein surface region that is
affected by ADH-6 interaction, based on the NMR evidence,
should not suggest the occurrence of a rather generic interaction
altogether. Approximately 75% of residues involved in the
clusters of Fig. 2d are predicted to be aggregation prone14, which
provides a basis for the effect of ADH-6 on sensitive locations
other than p53251–258 in p53 DBD. Chemical shift changes,
however, may also be the consequence of local rearrangements in
response to an allosteric interaction. Therefore, only part of the
highlighted surface regions of Fig. 2d may actually be directly
involved in the dynamic contacts with ADH-6. A possible clue for
the determination of these contacts may come from the
inspection of the relative peak intensities (RI), i.e. the ratio of
the peak heights in the presence and absence of ADH-6
(Supplementary Section 2). Dynamic interactions may in fact
induce intensity attenuations because of exchange and/or dipolar
broadening, thereby providing a further interpretation tool.


































































































Fig. 2 NMR-based determination of p53 DBD–ADH-6 interaction interface. a, b Overlay of 15N-1H HSQC maps of 19 μM WT (a) and 24 μM R248W (b)
p53 DBD in H2O/D2O (96/4) with 16.7 mM DTT, without (green contours) or with (red contours) ADH-6 addition (protein:ligand 1:11 in a and 1:15 in b).
The assignments are reported only outside the rightmost regions. These regions are crowded because of the presence of partially unfolded species that
also interact with ADH-6 as highlighted by the boxed peak in each panel. c HSQC contour maps overlay of mutant R248W p53 DBD at different protein:
ADH-6 ratios (1:0 green, 1:8 cyan, and 1:15 red) showing the increment of cumulated chemical shift perturbation (CSP) with ligand concentration (Eq. 2).
d The five clusters of the two p53 DBD variants (WT and mutant R248W) that show high (>0.025) or medium (>0.015) CSP values137. Cluster 1
(highlighted in blue) includes residues T118, Y126, E271, C275, and G279; cluster 2 (highlighted in magenta) includes residues R196, E198, G199, L201,
Y220, and E221; cluster 3 (green) includes T102, Y103, Q104, G105, L257, L264, and R267; cluster 4 (orange) includes E171, R174, H179, R209, and G244;
and cluster 5 (cyan) includes S94, A161, I162, L206, and S215. Clusters 1 and 2 are at the front in the cartoon on the left; clusters 3–5 are at the front in the
cartoon on the right. The 3D image was generated using PyMOL 2.3.5 (Schrödinger, New York, NY).
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by more than one standard deviation from the average RI value
were observed for K120, T123, Q192, and R196 in the WT DBD,
and for Q192 and R196 in the mutant species. The first pair of
highly attenuated NHs in the WT variant suggests a contact at
cluster 1 (blue; Fig. 2d), close to the C-terminal helix, which is
consistent with the designed properties of ADH-6. The attenua-
tion of Q192 and R196 amide peaks points to a contact occurring
at cluster 2 in both species (magenta; Fig. 2d).
Besides attenuations, intensity increments were also observed
upon ADH-6 addition, suggesting an increase in local mobility at
residues of the C-terminal region (E298 and R306) and E271
(cluster 1). However, it was only with mutant R248W p53 DBD
that intensity increments were also sampled at L257 and L264
(cluster 3), thereby highlighting a hotspot mutation effect14,37. In
particular, for the mutant species, the mobility increase associated
with ADH-6 contact at cluster 2 (at least) seems to involve the
adjacent extremities of strands 3 (L264) and 4 (L257) of sheet B,
as well as at the opposite extremity of strand 3 (E271), in addition
to some points of the C-terminal region. Conversely, for the WT
DBD, the mobility increments accompanying ADH-6 contact
affect only the residues of the C-terminal region.
ADH-6 dissociates intracellular mutant p53 aggregates. Given
ADH-6’s potent antagonism of the self-assembly of the
aggregation-prone segment of mutant p53 DBD (Fig. 1e, f, h), as
well as its multiple interaction sites on the DBD (Fig. 2), we
probed the effects of the oligopyridylamide on intracellular
mutant p53 aggregates (Fig. 3). MIA PaCa-2 cells harboring
aggregation-prone mutant R248W p53 were stained with thio-
flavin S (ThS), which is commonly used as a marker for intra-
cellular amyloid aggregates, including those of mutant p53
(refs. 36,39) (Fig. 3a, b). For some experiments, MIA PaCa-2 cells
were co-stained with ThS and the anti-p53 antibody PAb 240
(Fig. 3c–f). PAb 240 is specific for partially unfolded p53 as it
recognizes an epitope (residues 213–217; Fig. 1a, b) that is buried
in folded p53. Since p53 aggregation requires partial unfolding of
the protein, PAb 240 is often used as a marker for aggregated p53
(ref. 14).
Punctate cytosolic ThS staining was observed in MIA PaCa-2
cells, indicating that mutant R248W p53 self-assembles into
amyloid aggregates in the cytosol (Fig. 3a, c). Treatment with
ADH-6 for 6 h led to a substantial reduction in the number of
ThS-positive puncta, with the proportion of cells containing these
puncta decreasing to ∼30% (Fig. 3a, b). Strong colocalization of
the ThS and PAb 240 signals was observed in the vehicle-treated
control cells (Fig. 3c), confirming that ThS stains cytosolic mutant
p53 aggregates. Treatment of dual-stained MIA PaCa-2 cells with
ADH-6 markedly reduced both the ThS and PAb 240 signals
(Fig. 3c). The effect of ADH-6 on mutant p53 aggregates was dose
dependent, with the PAb 240-positive cells decreasing to ∼50 and
24% of controls at 5 and 10 µM ADH-6, respectively (Fig. 3f).
Treatment with ReACp53, which has been reported to disag-
gregate mutant p53 in clinical samples and stable cells established
from patients14, also significantly reduced the proportion of ThS-
and PAb 240-positive cells (PAb 240-positive cells were ∼40% of
controls at 10 µM ReACp53) (Fig. 3e and Supplementary Fig. 7).
In contrast, ADH-1, which did not antagonize pR248W
aggregation (Fig. 1e, f, h), had a negligible effect on the ThS or
PAb 240 staining (Fig. 3d and Supplementary Fig. 7).
As a control, we tested the effects of ADH-1, ReACp53, and
ADH-6 on mutant p53 DBD aggregates in plant cells. p53 is not
found in plants, which are usually (i.e. in the absence of
pathogens) not susceptible to neoplasia40. Yet, remarkably, stable
transfection of p53 in the model plant Arabidopsis was shown to
induce early senescence41. Thus, plants represent a viable system
for studying mutant p53 DBD aggregation. Here, we amplified
the genes using primers corresponding to p53 DBD and cloned
them in a binary vector expressing an N-terminal yellow
fluorescence protein (YFP) tag, under the control of cauliflower
mosaic virus (CaMV35S) promoter. The cloned constructs, YFP-
tagged WT and mutant R248W p53 DBDs (YFP:p53DBDWT and
YFP:p53DBDR248W, respectively), were subsequently expressed in
Nicotiana benthamiana using Agrobacterium-mediated transient
infiltrations. While the WT DBD accumulated exclusively in the
nucleus, expression of R248W p53 DBD resulted in a number of
foci spread throughout the cell (Supplementary Fig. 8a), indicat-
ing that the mutant protein forms cytosolic aggregates in plant
cells similar to those detected in mammalian cells (Fig. 3 and
Supplementary Fig. 7). Treatment of the N. benthamiana leaves
with ADH-6 or ReACp53 resulted in significantly smaller puncta
in the cells expressing the mutant p53 DBD (Supplementary
Fig. 8a, c). Our results are in agreement with reports that
ReACp53 disaggregates cytosolic mutant p53 puncta14,42, which
leads to accumulation of the released protein in the nucleus14. On
the other hand, ADH-1 did not reduce the size of mutant R248W
DBD puncta (Supplementary Fig. 8a, c).
To corroborate the imaging results, MIA PaCa-2 cells were
treated with ADH-1, ReACp53 or ADH-6, lysed and fractionated,
and the amount of mutant R248W p53 in the soluble and insoluble
fractions was quantified by western blot (Supplementary Fig. 9). As
expected, treatment with ADH-1 did not alter the distribution of
mutant p53 relative to the vehicle-treated controls, with the
aggregation-prone protein strongly detected in the insoluble
fraction, but almost completely absent from the soluble fraction.
However, treatment with ADH-6 or ReACp53 significantly
decreased the mutant p53 content of the insoluble fraction, while
markedly increasing the amount of protein in the soluble fraction.
These results confirm that ADH-6 converts insoluble cytosolic
mutant p53 aggregates into soluble protein.
In order to ascertain whether ADH-6-mediated dissociation of
mutant R248W p53 aggregates is a result of direct interaction
with the oligopyridylamide, PAb 240-stained MIA PaCa-2 cells
were treated with FITC-labeled ADH-6 (ADH-6FITC) (Fig. 3g).
Initially, strong colocalization of ADH-6FITC and PAb 240 was
observed, indicating direct interaction of the oligopyridylamide
with mutant p53 aggregates. Eventually, the extent of colocaliza-
tion decreased as the PAb 240 staining was reduced due to
disaggregation of mutant p53. Intracellular target engagement
was further confirmed using the cellular thermal shift assay
(CETSA), which measures ligand-induced changes in thermal
stability of target proteins43,44. The labile WT p53 has a melting
temperature (Tm) of ∼45 °C, and mutations destabilize the
protein further and lower its Tm by 5–10 °C6,45. Consistent with
these reports, CETSA generated melting curves in MIA PaCa-2
and SK-BR-3 cells yielded Tm of 39.6 ± 1.5 and 38.8 ± 1.4 °C for
p53 mutants R248W and R175H, respectively (Fig. 3h, i and
Supplementary Fig. 10). Treatment of the cells with ADH-6, but
not ADH-1, significantly increased Tm to 48.2 ± 0.9 and 45.1 ±
1.2 °C for R248W and R175H, respectively (Fig. 3h, i and
Supplementary Fig. 10), indicating strong stabilization of
aggregation-prone mutant p53 by the oligopyridylamide. Taken
together, these results show that, similar to ReACp53 (ref. 14),
ADH-6 efficiently enters cells to directly interact with and
stabilize mutant p53, which shifts the folding equilibrium towards
the soluble state, leading to dissociation of the protein’s inactive
amyloid-like cytosolic aggregates.
ADH-6 causes selective cytotoxicity in cancer cells bearing
mutant p53. Next, we determined the effects of the oligopyr-
idylamides on viability of mutant p53-harboring cancer cells
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using the MTS assay. A screen of the compounds revealed a
strong correlation between their toxicity in mutant R248W p53-
bearing MIA PaCa-2 cells (Fig. 4a and Supplementary Fig. 11a, b)
and their capacity to antagonize pR248W aggregation (Fig. 1e, f
and Supplementary Fig. 1b). Indeed, ADH-6, which was the most
potent antagonist of pR248W amyloid formation, was also the
most toxic compound to MIA PaCa-2 cells. ADH-6 reduced MIA
PaCa-2 cell viability in a concentration-dependent manner, with
an effective concentration (EC50) of 2.7 ± 0.4 and 2.5 ± 0.1 µM at
24 and 48 h incubation times, respectively (Fig. 4a), which was
almost half of that for ReACp53 (EC50= 5.2 ± 0.5 and 4.9 ± 0.3
µM at 24 and 48 h incubation, respectively) (Supplementary
Fig. 11d). On the other hand, ADH-1, which did not inhibit
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PaCa-2 cells (Fig. 4a). Importantly, the oligopyridylamides,
including ADH-6, were completely nontoxic to WT p53-bearing
breast cancer MCF-7 cells (Fig. 4b and Supplementary Fig. 11c).
Moreover, treatment of a range of human cancer cells bearing
WT p53 (AGS, A549, CAKI-1, CESS, LS 174T, MDA-MB-175-
VII, NCI-H1882, SH-SY5Y, and U-2 OS) with ADH-6 yielded no
significant toxicity (Supplementary Fig. 11e). Conversely, the
oligopyridylamide was highly toxic to mutant R175H p53-bearing
SK-BR-3 cells (EC50= 2.6 ± 0.1 and 2.5 ± 0.2 µM at 24 and 48 h
incubation, respectively) (Fig. 4c). Likewise, we observed a sub-
stantial (∼75–95%) decrease in viability of human cancer cells
harboring other aggregation-prone p53 mutants (R248W: COLO
320DM and NCI-H1770; R248Q: HCC70 and OVCAR-3; R175H:
LS123; R273H: HT-29 and ARH-77; Y220C: NCI-H748 and NCI-
H2342; and R280K: MDA-MB-231) following treatment with
ADH-6 (Supplementary Fig. 11f).
Notably, ADH-6 did not adversely affect viability of p53 null
human bone cancer Saos-2 cells (Fig. 4d). However, transfecting
the cells with mutant R248W or R175H p53 rendered them
highly susceptible to ADH-6 mediated cytotoxicity (EC50= 2.0 ±
0.2 and 2.3 ± 0.2 µM for R248W and R175H, respectively, at 48 h
incubation) (Fig. 4e, f and Supplementary Fig. 12a). Similarly, p53
null human ovarian cancer SKOV-3 cells were unaffected by
treatment with ADH-6, but following transfection with R248W or
R175H, the oligopyridylamide induced significant toxicity in the
cells (Supplementary Fig. 12a–d). Together with the screen of
cancer cells bearing WT and mutant p53, these results indicate
that the observed cytotoxicity of ADH-6 in cancer cells is directly
related to the oligopyridylamide’s capacity to antagonize mutant
p53 amyloid formation.
A marker of restored p53 function is activation of apoptosis.
Therefore, following treatment with vehicle, or 5 µM ADH-1,
ReACp53, or ADH-6, MIA PaCa-2 cells were stained with Alexa
488-conjugated annexin V/propidium iodide (PI) and quantified
by flow cytometry, a common method for detecting apoptotic
cells46 (Fig. 4g, h and Supplementary Fig. 13a). As expected,
treatment with ADH-1 had a negligible effect. Exposure to
ReACp53 resulted in 75.7 ± 1.1% and 2.0 ± 0.2% of cells under-
going early and late apoptosis, respectively, which is in line with
the reported capacity of the peptide to induce apoptosis in
aggregation-prone mutant p53-bearing cancer cells14. However,
treatment with ADH-6 led to an even more pronounced effect,
with 11.4 ± 0.9% and 77.9 ± 1.3% of cells undergoing early and
late apoptosis, respectively. The rescue of p53 activity was further
corroborated by cell cycle analysis (Fig. 4i and Supplementary
Figs. 11g and 13b). In contrast to ADH-1, treatment with
ReACp53 resulted in a small but significant shift in the cell cycle
distribution of the asynchronous population, which is a hallmark
of p53 activation14. However, yet again we observed an even
greater effect following exposure to ADH-6, with a larger shift in
the cell cycle distribution occurring (i.e. more cells in the G0/G1
phase and fewer in G2/M) relative to ReACp53. Collectively, our
results strongly suggest that ADH-6-mediated cytotoxicity in
cancer cells is due to abrogation of mutant p53 aggregation by the
oligopyridylamide, which leads to recovery of WT p53 function.
ADH-6 induces transcriptional reactivation of p53. To confirm
that ADH-6 rescues p53 function, we first used ChIP-qPCR to
detect recruitment of mutant R248W p53 to the WT protein’s
binding sites on promoters/enhancers of target genes in
oligopyridylamide-treated MIA PaCa-2 cells (primers used are
listed in Supplementary Table 1). Treatment with ADH-6 led to
binding of R248W to Cdkn1a (also known as P21) (Supple-
mentary Fig. 14a). Importantly, we did not detect significant
binding of the p53 homologs, p63 and p73, to Cdkn1a under the
same experimental conditions (Supplementary Fig. 14a), sup-
porting the notion that ADH-6 activity is mutant p53 dependent.
Interaction of R248W with other well-established primary p53
transcriptional targets, PIG3 and NOXA, was also observed in
ADH-6 treated MIA PaCa-2 cells (Supplementary Fig. 14b, c).
(Please note that functions of the genes referenced in this section
are described in Supplementary Section 4.)
In agreement with the ChIP-qPCR results, western blot
analysis revealed elevated expression of both p21 and Noxa in
ADH-6-treated MIA PaCa-2 cells (Supplementary Fig. 15).
Interestingly, we also observed significantly higher expression of
p53-inducible MDM2 and proapoptotic Bax in response to ADH-
6 treatment (Supplementary Fig. 15). Surprisingly, recruitment to
the MDM2 and BAX genes was not observed by ChIP-qPCR,
which may be a consequence of the interaction of mutant p53
with the WT protein’s binding sites on the promoters of these
genes being too transient or weak to be detected by the assay47,48.
Of relevance, the mutant p53 disaggregating peptide ReACp53
was also reported to upregulate p21, Noxa, MDM2, and Bax in
ovarian cancer cells that harbor another aggregating p53 mutant,
R248Q14. Taken together, these results indicate that ADH-6
specifically targets and reactivates aggregation-prone mutant p53.
Next, transcriptome analysis was performed to assess the
effects of ADH-6 on the mutant p53-bearing cells at the global
gene level (Fig. 5). Total RNA samples were isolated from ADH-
6, ADH-1, and vehicle (control, C) treated cells, which was
followed by RNA-Seq library preparation. To establish the best
condition for differential gene expression analysis, we applied
correlation analysis to the data (Supplementary Fig. 16a). As
assessed by principal component analysis (PCA), there were
variable clustering patterns within and between samples, showing
Fig. 3 ADH-6 dissociates mutant p53 aggregates in cancer cells. a Confocal fluorescence microscopy images showing thioflavin S (ThS) staining of
mutant p53 (R248W) aggregates in MIA PaCa-2 cells treated with vehicle (0.02% DMSO) or ADH-6 (5 µM) for 0.5 or 6 h. Imaging experiments were
performed in quadruplicate and representative images are shown. b Quantification of ThS-positive MIA PaCa-2 cells after treatment with vehicle or ADH-
6. The number of positively stained cells in 3–5 different fields of view are expressed as % of the total number of cells (n= 4 biologically independent
samples). Data presented are mean ± SD. Statistical analysis was performed using two-tailed unpaired t-test. P < 0.0001 for ADH-6 vs vehicle at 6 h.
c Confocal fluorescence microscopy images of ThS and PAb 240 antibody staining of R248W aggregates in MIA PaCa-2 cells treated with vehicle or 5 µM
ADH-6 for 0.5 or 6 h. Images shown are representative of four independent experiments. d–f Quantification of PAb 240-positive MIA PaCa-2 cells after
treatment with the indicated concentrations of ADH-1, ReACp53, or ADH-6 for 0.5 or 6 h relative to controls (vehicle-treated cells). The number of
positively stained cells in 3–5 different fields of view are expressed as % of the total number of cells (mean ± SD; n= 4). Statistical analysis was performed
using repeated measures two-way ANOVA followed by Holm-Sidak’s post hoc test. P < 0.0001 for ReACp53 (2.5–10 µM) vs vehicle at 6 h (e); P < 0.0001
for ADH-6 (2.5–10 µM) vs vehicle at 6 h (f). g Colocalization of FITC-labeled ADH-6 (ADH-6FITC) with PAb 240-stained R248W aggregates following
incubation with the oligopyridylamide (5 µM) for 0.5 or 6 h. Colocalization was quantified using directional Pearson correlation coefficient, r, which
measures pixel-by-pixel covariance in the signal level of two images132. Scale bar= 5 µm. h, i Cellular thermal shift assay (CETSA) analysis of intracellular
target engagement. Melting curves for p53 mutants R248W (h) and R175H (i) in MIA PaCa-2 and SK-BR-3 cells, respectively, in the absence or presence
of the oligopyridylamides (mean ± SD; n= 3). ***P < 0.001 or non-significant (n.s., P > 0.05) for comparisons with vehicle-treated controls.
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the highest effect to be based on the treatment at PC1: 36%
(Supplementary Fig. 16a). ADH-6 treated cell replicates were
observed to cluster independently from ADH-1 and C sample
replicates. Subsequently, the number of differentially expressed
genes (DEGs) was determined based on statistical cut-offs,
including P-adj < 0.05, P-adj < 0.01 and P-adj < 0.001 between
pairwise comparisons of ADH-6/C, ADH-1/C, and ADH-6/
ADH-1. The number of DEGs varied, with the highest observed
for ADH-6/C at 485 genes at P-adj < 0.05 (Supplementary
Fig. 16b).
In order to further probe the effects of ADH-6 treatment, the
expression patterns of the 485 DEGs identified were analyzed
using hierarchical clustering (performed by the JMP Genomics
software) following variance-stabilizing transformation (VST) of
the count data. As shown in the heatmap, distinctive clustering
patterns were observed, with 196 DEGs identified as upregulated,
while 289 were downregulated, in the ADH-6 treatment group
relative to the vehicle-treated controls (ADH-6/C) (Fig. 5a). To
characterize the functions of these DEGs, Gene Ontology (GO)
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process” category (Fig. 5b). With a P-value <0.05 (normalized to
−log10) cut-off, several biological process enrichments were
identified, the top five of which were related to regulation of cell
cycle (GO:0051726), cell cycle arrest (GO:0007050), cell prolif-
eration (GO:0008283), regulation of apoptosis (GO:0042981) and
aging (GO:0007568) (Fig. 5b). A Venn diagram was then used to
delineate overlap of DEGs between the selected processes in order
to remove redundancies (Fig. 5c). Based on the Venn diagram,
the selected enrichments were further refined into a finalized
DEGs list, as displayed in the heatmap (scaled to log2 count per
million reads (log2cpm_voom)) generated using DESeq2 (Fig. 5d).
From the heatmap, 25 DEGs were identified as upregulated,
whereas 49 were downregulated, in ADH-6/C.
The observed expression patterns strongly support transcrip-
tional activation of p53 by ADH-6. In agreement with the ChIP-
qPCR analysis, treatment of MIA PaCa-2 cells with ADH-6
resulted in significant (0.7–1.3-fold) upregulation of Cdkn1a
relative to both the ADH-1 and control groups (Fig. 5e). ADH-6
treatment also significantly upregulated other p53 target genes
that are important mediators of cell cycle arrest and
apoptosis49–51 (Fig. 5e). For instance, a 0.4-fold upregulation of
the tumor protein p53-inducible nuclear protein 1 (Tp53inp1)
was observed in the ADH-6 treatment group compared to
controls. Likewise, ADH-6 induced a 0.6–1-fold upregulation of
FOS relative to treatment with vehicle or ADH-1. Finally,
treatment with ADH-6 resulted in a 0.9–1.3-fold upregulation
of EGR1 compared to both the vehicle and ADH-1 treatment
groups. On the other hand, exposure to ADH-6 led to significant
downregulation of p53 targets TP73 and SIX1 (Fig. 5e). ADH-6
induced a 1-fold downregulation of TP73 compared to controls.
Interestingly, downregulation of p73 was observed following
treatment of mutant p53-bearing cells with ReACp53 (ref. 14).
ADH-6 treatment also resulted in a 0.3–0.5-fold downregulation
of the SIX1 oncogene relative to both controls and ADH-1
treatment groups.
Lastly, we performed ingenuity pathway analysis (IPA) of the
DEGs to identify the upstream transcriptional regulators (TRs) of
these genes. Over a dozen TRs were activated in the ADH-6 group,
and the 10 candidates shown were identified on the basis of their q-
value and z-score thresholds (Supplementary Fig. 17a, b). Of these
TRs, TP53 showed robust activation as indicated by the highest q-
value in both the ADH-6 vs vehicle (Supplementary Fig. 17a) and
ADH-6 vs ADH-1 (Supplementary Fig. 17b) comparisons. Forty-
two genes in the ADH-6 vs control comparison and 44 in the
ADH-6 vs ADH-1 comparison (Supplementary Fig. 17c) showed
an expression pattern that signified the activation of the TP53
pathway. To further determine the biological consequence of
ADH-6-mediated p53 activation, gene set enrichment analysis
(GSEA) was performed (Supplementary Fig. 17d). The findings of
IPA were corroborated using this approach as the TP53 pathway
was shown to be induced in the ADH-6 treatment group when
compared to the ADH-1 group. Activation of the TP53 pathway
was strongly supported by the observed suppression of the MYC
pathway, which is known to be negatively regulated by p53 (ref. 52).
Furthermore, the gene set for cell death/apoptosis was activated
and the genes involved in cell cycle progression (G2/M) were
suppressed in the ADH-6 treatment group. Collectively, these
findings strongly point to ADH-6 reactivating the p53 transcrip-
tional response in aggregation-prone mutant p53-bearing cancer
cells.
ADH-6 downregulates cancer-promoting phosphoproteins. We
subsequently carried out proteome analysis of oligopyridylamide-
treated MIA PaCa-2 cells. We chose to focus specifically on the
phosphoproteome (Supplementary Fig. 18) as many phospho-
proteins are involved in regulating major pathways implicated in
cancer53–57. Unsupervised hierarchical clustering (UHC) revealed
two distinct expression profiles pertaining to the ADH-1 and
the ReACp53/ADH-6 treatment groups (Fig. 6a). PCA analysis
further highlighted that the main source of variation in the
two groups was the peptide/compound treatment (Fig. 6a, b).
Moreover, compared to ADH-1, most of the phosphoproteins
downregulated upon ReACp53 treatment were also down-
regulated in the ADH-6 samples (Fig. 6c). Next, we carried out
GSEA of hallmark signatures for the differentially expressed
phosphoproteins. We observed a comparable reduction of phos-
phoprotein expression, in a number of pathways, in the ReACp53
and ADH-6 treated cells compared to the ADH-1 treatment
group (Fig. 6d).
The biological roles of the downregulated phosphoproteins
were inferred from published data (Supplementary Table 2), and
revealed that these proteins can be divided into two major
functional groups that positively regulate either DNA replica-
tion/repair or cell cycle progression/proliferation, although many
downregulated proteins in the ADH-6 treatment group had
overlapping gene signatures (Fig. 6e). Importantly, these two
major groups, which play a critical role in cancer initiation and
progression, are known to be directly regulated by p53
(refs. 58–62). This strongly supports that both the ReACp53
and ADH-6 treatments result in reactivation of p53, which
Fig. 4 ADH-6 causes death of cancer cells bearing mutant, but not WT, p53. a–c Effects of ADH-6 on viability of cancer cells bearing WT or mutant p53.
MIA PaCa-2 (mutant R248W p53) (a), MCF-7 (WT p53) (b), and SK-BR-3 (mutant R175H p53) (c), cells treated with increasing oligopyridylamide
concentrations for 24 or 48 h. (d–f) p53 null Saos-2 cells before (d) and after transfection with p53 mutants, R248W (e) or R175H (f), treated with
increasing concentrations of ADH-6 for 24 or 48 h. Cell viability in a–f was assessed using the MTS assay, with the % viability determined form the ratio of
the absorbance of the treated cells to the control cells (n= 3 biologically independent samples). Data presented are mean ± SD. Statistical analysis in a–f
was performed using two-tailed unpaired t-test. P < 0.0001 for ADH-6 vs ADH-1 at the same compound concentration (2.5–10 µM) and incubation time
(24 or 48 h) (a, c); P < 0.0001 for ADH-6 treatment of Saos-2/R248W compared with untransfected cells (data shown in d) at the same compound
concentration (2.5–10 µM) and incubation time (24 or 48 h) (e); P < 0.0001 for ADH-6 treatment of Saos-2/R175H compared with untransfected cells
(data shown in d) at the same compound concentration (2.5–10 µM) and incubation time (24 or 48 h) (f). g, h Flow cytometry analysis of annexin V/
propidium iodide (PI) staining of MIA PaCa-2 cells that were treated with vehicle (control), or 5 µM ADH-1, ReACp53, or ADH-6, for 24 h. The bottom left
quadrant (annexin V−/PI−) represents live cells; bottom right (annexin V+/PI−), early apoptotic cells; top right (annexin V+/PI+), late apoptotic cells;
and top left (annexin V−/PI+), necrotic cells (g). A summary of the incidence of early/late apoptosis and necrosis in the different treatment groups
determined from the flow cytometry analysis of annexin V/PI staining (mean ± SD; n= 4) (h). Statistical analysis in h was performed using one-way
ANOVA followed by Dunnett’s post hoc test. P < 0.0001 for ReACp53 vs vehicle (live and early apoptosis); P < 0.0001 for ADH-6 vs vehicle (live, early
apoptosis, and late apoptosis). i Cell cycle distribution of MIA PaCa-2 cells treated with vehicle (control), or 5 µM ADH-1, ReACp53 or ADH-6, for 6 h as
determined by measurement of DNA content using flow cytometry (mean ± SD; n= 4). Two-tailed unpaired t-test: P= 0.0071 and 0.0037 for ReACp53 vs
vehicle (G0/G1 and G2/M, respectively); P < 0.0001 and P= 0.0004 for ADH-6 vs vehicle (G0/G1 and G2/M, respectively). **P < 0.01, ***P < 0.001 or
non-significant (n.s., P > 0.05) for comparisons with vehicle-treated controls.
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downregulates key cancer-promoting phosphoproteins (Supple-
mentary Table 2a). Indeed, numerous studies have reported that
p53 directly downregulates the expression of key positive
regulators of cancer in the p53 pathway, such as CD44 (ref. 63)
and PCNA64,65, as well as the oncoproteins c-Myc52,66, E2F67,68,
and mTORC169–71 (Supplementary Fig. 19). Interestingly, only a
few upregulated phosphoproteins were identified in our
phosphoproteome screen (Fig. 6f and Supplementary Table 2b).
Together, the transcriptomic and proteomic analyses clearly
demonstrate that ADH-6-mediated dissociation of mutant p53
amyloid-like aggregates in cancer cells restores p53 function,
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In vivo administration of ADH-6 causes regression of mutant
p53-bearing tumors. Having established that ADH-6 potently
abrogates mutant p53 amyloid formation and restores WT-like
tumor suppressor function in vitro, we next assessed the in vivo
efficacy of the oligopyridylamide (Fig. 7 and Supplementary
Figs. 20 and 21). Following intraperitoneal (IP) injection, ADH-6
quickly entered circulation, with the peak concentration in serum
mice (~21 µg/mL) occurring at 2 h post-injection (Fig. 7a). The
in vivo circulation half-life72 of ADH-6 (T1/2 ~3.6 h) was much
longer than that of ReACp53 (T1/2 ~1.5 h)14, or other che-
motherapeutics of a comparable size, such as doxorubicin (T1/2 <
30 min)73 or paclitaxel (T1/2 ~1.7 h)74. Moreover, ADH-6 was
detected in the plasma up to 48 h after administration, whereas
ReACp53 was largely eliminated from the bloodstream in 24 h14.
The relatively long in vivo circulation time of ADH-6 should
facilitate greater accumulation in tumor tissue. Indeed, the
amount of ADH-6 in the MIA PaCa-2 xenografts increased
continuously over 48 h post-treatment (Fig. 7b). The high in vivo
stability suggested that ADH-6 would exhibit potent antitumor
activity.
To test this hypothesis, mice bearing MIA PaCa-2 xenografts
were treated with ADH-6, ADH-1 or ReACp53 (155.6 µM in
PBS) (Supplementary Fig. 20a, b). Treatment consisted of IP
injections every 2 days, for a total of 12 doses (Supplementary
Fig. 20b). IP injection was used since this is the preferred
administration route for the control ReACp53 peptide14. As
expected, ADH-1 did not affect tumor growth (Supplementary
Fig. 20d–f). Conversely, both ADH-6 and ReACp53 reduced
tumor growth relative to the saline-treated control group.
However, of the two treatments, ADH-6 exhibited significantly
greater antitumor efficacy (Supplementary Fig. 20d–f). The effects
of the oligopyridylamides were recapitulated in mice bearing SK-
BR-3 xenografts, with ADH-6 again reducing tumor growth
substantially compared to ADH-1 (Supplementary Fig. 21).
To confirm its specificity for aggregation-prone mutant p53
in vivo, we tested ADH-6 in a dual xenograft model: mice bearing
MIA PaCa-2 (mutant R248W p53) xenografts on one flank and
MCF-7 (WT p53) xenografts on the other flank as an internal
control (Fig. 7c). For this model, treatment consisted of IP
injections every 2 days, for a total of 12 doses, of ADH-6 or
ReACp53 (716.4 µM in 0.02% DMSO) or vehicle (0.02% DMSO)
(Fig. 7d). DMSO was introduced to increase the solubility of
ADH-6 and allow administration of a higher dose of the
oligopyridylamide and ReACp53, which was comparable to that
used in the study by Eisenberg et al.14. While treatment with
ADH-6 or ReACp53 did not have a significant effect on growth of
the MCF-7 xenografts, both the protein mimetic and peptide
markedly reduced the MIA PaCa-2 tumor growth relative to the
vehicle-treated control group (Fig. 7f–i). Following treatment with
ReACp53, the tumors increased from an initial volume of 25 ± 2 to
29 ± 1 mm3 (compared to an increase from 25 ± 1 to 44 ± 2mm3
in the vehicle-treated controls; Fig. 7f), and the tumor mass was
~30% that of the controls (Fig. 7h, i). However, ADH-6 again
exhibited significantly greater antitumor efficacy than ReACp53.
Treatment with the oligopyridylamide reduced the MIA PaCa-2
xenografts from an initial volume of 26 ± 2 to 17 ± 2;mm3 (Fig. 7f),
and decreased the tumor mass to ~3% that of the controls (Fig. 7h,
i). Moreover, ADH-6 prolonged survival appreciably compared to
ReACp53 (Fig. 7n and Supplementary Fig. 20g).
Histological analysis of tumor tissues using hematoxylin and
eosin (H&E) staining confirmed the higher potency of ADH-6
compared to ReACp53 against MIA PaCa-2 xenografts (Fig. 7j
and Supplementary Fig. 20h). Immunohistochemistry (IHC)
analysis of residual tumor sections revealed that treatment with
ADH-6 strongly reduced mutant p53 levels in the MIA PaCa-2
xenografts, but did not significantly alter the amount of WT p53
in MCF-7 xenografts (Fig. 7k–m). Thus, ADH-6 effectively
targets aggregation-prone and inactive mutant, but not functional
WT, p53 in vivo.
ADH-6 and ReACp53 did not adversely affect the body weight
of treated mice (Fig. 7e and Supplementary Figs. 20c and 21c),
and H&E-stained heart, lung, liver, kidney, and spleen sections
showed no apparent abnormalities or lesions (Supplementary
Figs. 22 and 23). Our observations are in agreement with the
reported high tolerability and lack of measurable toxicity in
healthy tissue in vivo of ReACp53 (ref. 14). Taken together, these
results demonstrate that ADH-6 potently shrinks xenografts
harboring aggregation-prone mutant p53 in vivo, while exhibiting
no toxicity to healthy tissue, leading to markedly prolonged
survival.
Discussion
A wide range of disorders are associated with misfolding and self-
assembly of functional proteins or peptides into amyloids, which
are aggregates that are characterized by a fibrillar morphology, a
predominantly β-strand secondary structure, high thermo-
dynamic stability, insolubility in common solvents, and resistance
to proteolytic digestion75–77. These amyloid diseases include AD,
T2D, Parkinson’s disease, transmissible spongiform encephalo-
pathies (or prion diseases), and Huntington’s disease76,77. Rather
unexpectedly, it is now evident that a subset of mutant p53-
associated cancers can also be classed as amyloid diseases. The
conformationally flexible p53 normally exists in an equilibrium
between native/folded, partially unfolded and aggregated
states14,78. At the core of p53 is the thermodynamically unstable
DBD, which houses the vast majority of cancer-associated
mutations9,10. Many of these mutations destabilize the DBD
further and prompt its unfolding, leading to exposure of the
normally hidden aggregation-nucleating subdomain, p53251–258
(refs. 13,14). This shifts the equilibrium towards the aggregated
Fig. 5 Transcriptome analysis of oligopyridylamide-treated MIA PaCa-2 cells. a Variance-stabilized count data heatmap showing clustering patterns of
differentially expressed genes (DEGs) identified based on statistical significance of P-adj < 0.05 from the ADH-6 treatment group relative to vehicle-
treated controls (C) (denoted ADH-6/C). Significance was assessed by false discovery rate (FDR) adjusted P-value (P-adj or q-value), which was obtained
from the hypergeometric P-value that was corrected for multiple hypothesis testing using the Benjamin and Hochberg procedure122. The ADH-1 treatment
group is included for comparison. The adjacent legend indicates the scale of expression, with red signifying upregulation, and blue downregulation, in ADH-
6/C. b Gene ontology (GO) analysis of ADH-6/C showing the top five “biological process” term enrichments based on a cut-off of P-value <0.05
(normalized to −log10). Statistical analysis was performed using two-tailed unpaired t-test. c Venn diagram delineating overlap of DEGs between the
processes in b. d Heatmap (scaled to log2 counts per million reads (log2cpm_voom)) displaying a finalized list of DEGs based on the Venn diagram. e Gene
expression boxplots of DEGs selected from the heatmap in d (n= 3 biologically independent samples). The boxplots display the five-number summary of
median (center line), lower and upper quartiles (box limits), and minimum and maximum values (whiskers). Statistical analysis was performed using two-
tailed unpaired t-test. P < 0.0001 for Cdkn1a, FOS, EGR1, and SIX1, P= 0.0002 for Tp53inp1, and P= 0.0026 for TP73 (ADH-6/C); P < 0.0001 for Cdkn1a,
FOS, and EGR1, P= 0.0072 for Tp53inp1, P= 0.0471 for TP73, and P= 0.0019 for SIX1 (ADH-6/ADH-1). *P < 0.05, **P < 0.01, ***P < 0.001 or non-
significant (n.s., P > 0.05) for comparisons with vehicle-treated controls and between the different treatment groups.
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state13,14, culminating in sequestration of mutant p53 in inactive
cytosolic amyloid-like aggregates that often co-opt the WT iso-
form and its paralogs, p63 and p73 (ref. 17).
The amyloidogenic nature of mutant p53 aggregation was first
reported almost two decades ago79. Subsequent studies revealed
amyloid-like mutant p53 aggregates in cancer cell lines, in vivo
animal models and human tumor biopsies11,12. Increasing evi-
dence now implicates these aggregates in mutant p53-associated
loss of tumor suppressor function and oncogenic GoF3,5,12,14,17,19.
Intriguingly, there are reports of transmission of this oncogenic
GoF phenotype, whereby mutant p53 amyloid aggregates (in the
form of oligomers or fibril fragments) are trafficked to contiguous
cells and seed aggregation of endogenous p53, suggesting that
aggregation-prone mutant p53-bearing cancers share a common
mechanism of propagation with prion diseases11,12. It is therefore
rather surprising that, so far, there are only a handful of reports of
therapeutic strategies targeting mutant p53 aggregation. The most
notable of these is ReACp53, a sequence-specific peptide inhibitor
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that blocks mutant p53 aggregation by masking the DBD’s
aggregation-nucleating p53251-258 segment14,17. This prevents
further aggregation and shifts the folding equilibrium toward
p53’s functional, WT-like state. Treatment with ReACp53 rescued
p53 function in aggregation-prone mutant p53-bearing human
ovarian and prostate cancer cells, leading to inhibition of cell
proliferation in vitro and tumor shrinkage in vivo14,42. More
recently, a bifunctional small molecule (denoted LI), with a
structure based on the amyloid reporter ThT, was reported to
restore zinc binding in mutant p53 and to modulate its
aggregation80. LI inhibited mutant p53 aggregation and restored
the protein’s transcriptional activity, leading to apoptosis in
human gastric cancer cells in vitro. While promising, the in vivo
efficacy of LI is yet to be determined.
Here, we have extended our protein mimetic-based approach,
previously developed to modulate various aberrant PPIs20,21,23,
towards mutant p53 aggregation. Screening a focused library of
oligopyridylamide-based α-helix mimetics, we identified a catio-
nic tripyridylamide, ADH-6, that potently inhibited oligomer-
ization and amyloid formation of pR248W, a mutant p53 DBD-
derived peptide containing both the aggregation-nucleating
sequence and the commonly occurring R248W mutation, by
stabilizing the peptide’s native conformation (Fig. 1). It should be
noted that ADH-6 only modestly antagonized Aβ amyloid
formation20, indicating a degree of specificity of the oligopyr-
idylamide for mutant p53. Importantly, ADH-6 also dissociated
pre-formed pR248W aggregates, and prevented further aggrega-
tion of the peptide (Fig. 1). Subsequent studies in human pan-
creatic carcinoma MIA PaCa-2 cells harboring mutant R248W
p53 (Fig. 3 and Supplementary Figs. 7 and 9), and N. ben-
thamiana cells transfected with YFP-tagged WT and R248W p53
DBDs (Supplementary Fig. 8), showed that ADH-6 effectively
dissociates intracellular mutant p53 amyloid-like aggregates.
Evidence that these effects are due to direct intracellular target
engagement comes from the following experiments: (i) confocal
microscopy, where extensive colocalization of fluorescently
labeled ADH-6 with antibody-stained intracellular mutant p53
was observed; and (ii) CETSA, which demonstrated strong sta-
bilization of p53 mutants in cancer cells by ADH-6 (Fig. 3 and
Supplementary Fig. 10).
NMR spectroscopy was used to gain insights into the interac-
tions between ADH-6 and mutant R248W p53 DBD at the
molecular level. The experiments revealed that the α-helix
mimetic interacts with not only the aggregation-nucleating sub-
domain, but also several other regions of mutant p53 DBD
(Fig. 2). This is not surprising given that the DBD contains
several helical regions (Fig. 1), as well as non-helical regions in
which amino acids—from neighboring or distal parts of the
protein—nevertheless align to present target side-chains with a
topology that matches that of the surface functionalities of ADH-
6 (Fig. 2). On the other hand, ReACp53, by virtue of its sequence,
specifically targets the aggregation-nucleating subdomain
(p53251–258) of the DBD14. However, it has been shown that
mutant p53 unfolding may expose other aggregation-prone sites,
besides p53251–258, which can contribute to the protein’s self-
assembly and enable it to partially circumvent the inhibitory
effects of ReACp53 (ref. 81). Thus, the targeting of multiple
regions of mutant p53 DBD enables ADH-6 to antagonize
intracellular mutant p53 aggregation more effectively than
ReACp53.
Helical intermediates play a role in the amyloid assembly of not
only Aβ and IAPP, but also a number of other disease-associated
intrinsically disordered proteins, including α-synuclein (Parkin-
son’s disease), prion protein (PrP, prion diseases) and tau
(tauopathies)82–84. A distinct possibility is that the intrinsically
disordered mutant p53 aggregates via a similar pathway, whereby
destabilized α-helical intermediates transition to stable, β-sheet
rich amyloid aggregates. Indeed, there are reports that
aggregation-prone p53 mutants, and fragments of these proteins,
sample helical structures during the process of self-assembling
into amyloid fibers85,86. This raises the possibility that, in addi-
tion to the monomeric protein, ADH-6 also targets pre-amyloid
helical intermediates of mutant p53’s amyloid aggregation path-
way. By stabilizing mutant p53 in its monomeric or helical
intermediate states, ADH-6 is able to effectively prevent the
protein’s amyloid aggregation, thereby strongly shifting the
folding equilibrium towards the functional, WT-like state.
Treatment with ADH-6 resulted in substantial toxicity in
mutant R248W p53-bearing MIA PaCa-2 cells (Fig. 4). Several
lines of evidence from multiple experiments establish that ADH-6-
mediated cytotoxicity is directly related to the oligopyridylamide’s
capacity to antagonize mutant p53 amyloid formation: (i) a second
screen, testing the effects of the oligopyridylamides on viability of
MIA PaCa-2 cells (Fig. 4 and Supplementary Fig. 11), revealed a
strong correlation between the compounds’ cytotoxicity and their
capacity to antagonize pR248W aggregation (Fig. 1 and Supple-
mentary Fig. 1), and again identified ADH-6 as the most potent
compound in the library; (ii) ADH-6 is significantly more toxic to
MIA PaCa-2 cells than the control ReACp53 peptide (Fig. 4 and
Supplementary Fig. 11), which reflects their relative capacities to
abrogate intracellular mutant p53 aggregation (Fig. 3 and Sup-
plementary Figs. 7–9); (iii) ADH-6 induced substantial loss of
viability in a range of human cancer cells bearing aggregation-
prone mutant p53, but was completely nontoxic to WT p53
harboring human cancer cells (Fig. 4 and Supplementary Fig. 11);
and (iv) p53 null Saos-2 and SKOV-3 cells, which were insensitive
Fig. 6 Quantitative proteomic analysis of phosphoprotein expression in oligopyridylamide-treated MIA PaCa-2 cells. a Heatmap showing differentially
expressed phosphoproteins in ADH-1, ReACp53, and ADH-6 treated samples. Unsupervised hierarchical clustering reveals distinct segregation of ADH-1 vs
ReACp53 and ADH-6. b Results from principal component analysis (PCA) showing that the main source of variation in the indicated groups was the
compound/peptide treatment. c Venn diagram showing phosphoproteins that were differentially expressed in the ADH-6 vs ADH-1 and ReACp53 vs ADH-1
comparisons. The number of phosphoproteins that were unique or common in both comparisons are highlighted. d Gene set enrichment overlap analysis
(GSEA) of hallmark signatures for the differentially expressed and downregulated phosphoproteins. Significance was assessed by q-value, or false discovery
rate (FDR)-adjusted P-value, which was obtained from the hypergeometric P-value that was corrected for multiple hypothesis testing using the Benjamin and
Hochberg procedure122. The hallmark signatures were ranked based on the−log10(q-value) of overlap. Only gene signatures that were significantly different
(q-value <0.05 or −log10(q-value) >1.3) were further analyzed. e GOChord plot of phosphoproteins that belong to top dysregulated hallmark signatures
(shown in d). The plot also depicts overlap of phosphoproteins between indicated gene signatures. Fold change of phosphoproteins (ADH-6 vs ADH-1) is
represented by the blue track with the color spectrum depicting the level of reduction in phosphoprotein expression in the ADH-6 group. The biological roles
of the downregulated phosphoproteins in ADH-6 were inferred from published data. The outer layer of the GOChord plot links the downregulation of
phosphoproteins with the inhibition of DNA repair/replication and cell proliferation on the basis of previous reports (Supplementary Table 2a).
f Protein–protein interaction (PPI) network map of upregulated phosphoproteins in ADH-6 vs ADH-1 treatments (biological roles of upregulated
phosphoproteins are summarized in Supplementary Table 2b).
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to ADH-6 treatment, became highly susceptible to the cytotoxic
effects of the oligopyridylamide upon transfection with mutant
R248W or R175H p53 (Fig. 4 and Supplementary Fig. 12).
Further analysis of the effects of ADH-6 on mutant p53 har-
boring cancer cells revealed that the oligopyridylamide induces
cell cycle arrest and apoptosis, both of which are indicators of
restored p53 function (Fig. 4 and Supplementary Fig. 11). ADH-
6-mediated restoration of WT-like activity of mutant p53 was
confirmed using a number of complementary assays. ChIP-qPCR
analysis revealed that ADH-6 treatment resulted in recruitment of
mutant p53 to the WT protein’s primary transcriptional targets,
such as Cdkn1a, PIG3, and NOXA (Supplementary Fig. 14 and
Supplementary Table 1), that are not only key mediators of
p53-dependent cell cycle arrest and apoptosis87–91, but also
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determinants of the cytotoxic response of cancer cells to standard
chemotherapy and targeted cancer therapy92,93. Transcriptional
reactivation of mutant p53 was further corroborated using RNA-
Seq (Fig. 5 and Supplementary Figs. 16 and 17). Specifically, we
observed activation of the TP53 and apoptosis pathways, and
suppression of genes involved in cell cycle progression (G2/M)
and the MYC pathway, which are known to be negatively regu-
lated by p53 (ref. 52). Consistent with the transcriptome analysis,
western blot quantification of protein levels in MIA PaCa-2 cells
following treatment with ADH-6 revealed increased expression of
direct p53 targets (Supplementary Fig. 15). Additionally, phos-
phoproteome analysis showed that ADH-6 downregulates key
cancer-promoting phosphoproteins that are known to be directly
negatively regulated by p5358–62 (Fig. 6, Supplementary Figs. 18
and 19, and Supplementary Table 2). Taken together, our results
clearly demonstrate that ADH-6 dissociates mutant p53 amyloid-
like aggregates in cancer cells, and that the released protein is
restored to a functional form, which elicits the observed inhibi-
tion of proliferation via cell cycle arrest and induction of
apoptosis.
To establish whether the in vitro effects of ADH-6 are recapi-
tulated in vivo, we evaluated the effects of ADH-6 on mice bearing
MIA PaCa-2 (mutant R248W p53) or SK-BR-3 (mutant R175H
p53) tumors, alone or with MCF-7 (WT p53) tumors on the
opposite flank as an internal control (Fig. 7 and Supplementary
Section 5). ReACp53, serving as a positive control, reduced MIA
PaCa-2 tumor growth and prolonged survival relative to the
vehicle-treated control groups, which is in agreement with the
peptide’s reported ability to inhibit growth of aggregation-prone
mutant p53-bearing tumors14. However, ADH-6 was markedly
more effective at decreasing MIA PaCa-2 tumor volume and mass,
and prolonging survival, compared to ReACp53. The greater
in vivo efficacy of ADH-6 compared to ReACp53 correlates well
with their relative capacities to dissociate intracellular mutant p53
aggregates (Fig. 3 and Supplementary Figs. 7–9) and to induce
toxicity in mutant p53-bearing cancer cells (Fig. 4 and Supple-
mentary Fig. 11), as well as with their relative in vivo stabilities.
Peptides possess a number of pharmaceutically desirable proper-
ties, including the ability to selectively bind to specific targets with
high potency, thereby minimizing off-target interactions and
reducing the potential for toxicity94,95. On the other hand, a major
disadvantage of peptides is their low in vivo stability73. Synthetic
protein mimetics, with their constrained backbone, are inherently
more stable than peptides25,96, which is reflected in the sub-
stantially longer in vivo circulation half-life and prolonged pre-
sence in the bloodstream of ADH-6 relative to ReACp53. The
extended in vivo circulation time of ADH-6 facilitates increased
accumulation in tumor tissue and enhanced anticancer activity.
Importantly, ADH-6 exhibited high potency against MIA PaCa-2
and SK-BR-3 tumors but did not affect growth of control MCF-7
xenografts, underlining the oligopyridylamide’s specificity for
tumors that harbor aggregation-prone mutant p53. Additionally,
detailed necropsies of major organs revealed no damage or
alterations, demonstrating the lack of toxicity of ADH-6 to healthy
tissue. Thus, our results show that ADH-6 effectively shrinks
tumors bearing aggregation-prone mutant p53 in vivo, without
displaying the non-specific toxicity that is common to conven-
tional cancer therapeutics, thereby greatly prolonging survival.
Mutant p53-associated cancers are predicted to lead to the
deaths of more than 500 million people alive today97. This is
fueled, in part, by the increasing incidences of notoriously difficult
to treat malignancies, such as the highly lethal pancreatic cancer,
which is on course to becoming the second leading cause of cancer-
related mortality in Western countries within the next 5–10
years98. Consequently, there is a pressing need for new therapeutic
strategies to supplement or supplant current cancer treatments. In
the present study, we focused on a largely neglected—with a few
notable exceptions—property of a sizeable subset of p53 mutants,
namely their propensity to self-assemble into amyloid-like aggre-
gates. This aggregation is implicated in mutant p53-associated
tumor suppressor loss of function, oncogenic GoF and, potentially,
prion-like propagation of these phenotypes3,5,11,12,14,17,19. Testing
protein mimetics originally designed to antagonize amyloid for-
mation associated with AD and T2D20,21,23, we identified a
cationic tripyridylamide, ADH-6, that effectively abrogates mutant
p53 amyloid-like aggregation in human cancer cells, which restores
p53’s transcriptional activity, leading to cell cycle arrest and
induction of apoptosis. Importantly, ADH-6 treatment causes
Fig. 7 ADH-6 causes regression of tumors bearing mutant, but not WT, p53. a, b In vivo pharmacokinetics of ADH-6. Concentration of ADH-6 in plasma
(a) and in MIA PaCa-2 xenografts (b) of mice (n= 5–6 per group), after an intraperitoneal injection of the oligopyridylamide (15 mg kg-1), was quantified
using LC-MS/MS135. Shown are the circulation half-life (T1/2) (a) as well as the maximum (or peak) concentration (Cmax) in tumors and the time to achieve
Cmax (Tmax) (b). Data presented are mean ± SD. c, d Design of the tumor reduction studies. A representative mouse bearing both MIA PaCa-2 (mutant
R248W p53) and MCF-7 (WT p53) xenografts (c) and treatment schedule for the dual xenograft model (d). Once the tumor volume reached ~25mm3, the
mice were randomized into the different treatment groups (n= 8 per group), which were injected intraperitoneally with vehicle (0.02% DMSO), ReACp53
(716.4 µM), or ADH-6 (716.4 µM). Injections were done every 2 days for a total of 12 doses, with the first day of treatment defined as day 0. e Body weight
changes of the tumor-bearing mice in the different treatment groups monitored for the duration of the experiment (mean ± SD; n= 8). f, g Tumor volume
growth curves for the MIA PaCa-2 (f) and MCF-7 (g) xenografts in the different treatment groups over the duration of the experiment (mean ± SD; n= 8).
Tumor volume was calculated using Eq. (3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. P < 0.0001 for
ADH-6 vs vehicle, ReACp53 vs vehicle and ADH-6 vs ReACp53 (f). h, i Tumor mass analysis for the different treatment groups. After 25 days of
treatment, four mice per treatment group were sacrificed and the tumor tissues were isolated and imaged (h) and subsequently weighed to determine the
tumor mass (i). Data presented are mean ± SD, and statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. P <
0.0001 for ADH-6 vs vehicle, ReACp53 vs vehicle and ADH-6 vs ReACp53 (MIA PaCa-2 xenografts; i). j Hematoxylin and eosin (H&E)-stained xenograft
sections from the different treatment groups following 25 days of treatment. Images on the right are magnified views of the boxed regions in the images on
the left. Scale bar= 20 μm (50 μm for the magnified views). k–m Immunohistochemistry (IHC) analysis of the residual xenografts. Images of sections of
MIA PaCa-2 and MCF-7 xenografts stained using the anti-p53 PAb 240 and DO-7 antibodies, respectively, from the different treatment groups (k). Images
on the right are magnified views of the boxed regions in the images on the left. Scale bar= 20 μm (50 μm for the magnified views). Quantification of PAb
240 (l) and DO-7 (m) positive cells in 3–5 different fields of view expressed as % of the total number of cells (mean ± SD; n= 4). One-way ANOVA
followed by Tukey’s post hoc test: P < 0.0001 for ADH-6 vs vehicle, ReACp53 vs vehicle and ADH-6 vs ReACp53 (l). n Survival curves for the vehicle,
ReACp53 and ADH-6 treatment groups over 30 days (n= 4 per group). Statistical analysis was performed using log-rank (Mantel-Cox) test. P= 0.0062
for ADH-6 vs vehicle. **P < 0.01, ***P < 0.001 or non-significant (n.s., P > 0.05) for comparisons with vehicle-treated controls and between the different
treatment groups.
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regression of xenografts harboring mutant, but not WT, p53 and
prolongs survival, with no visible toxicity to healthy tissue. This
study effectively establishes a bridge between amyloid diseases and
cancer, providing a foundation for cross-informational approaches
in the design of potent mutant p53-targeted cancer therapeutics.
Methods
Reagents. 2-Deoxy-D-glucose, acetone, acetonitrile (ACN), 3′,5′-dimethoxy-4′-
hydroxyacetophenone (acetosyringone), bovine serum albumin (BSA), calcium
chloride (CaCl2), chloroform, dimethyl sulfoxide (DMSO), 1,4-dithiothreitol
(DTT), ethylenediaminetetraacetic acid (EDTA), gentamycin, glucose, glycolic acid,
N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP), indole-3-acetic acid (IAA), isoflurane, kanamycin,
lithium chloride (LiCl), magnesium chloride (MgCl2), methanol, 2-(N-morpho-
lino)ethanesulfonic acid (MES), N-hydroxysuccinimide (NHS), paraformaldehyde
(PFA), phosphotungstic acid (PTA), phosphate buffered saline (PBS), piperazine-
N,N′-bis(2-ethanesulfonic acid) (PIPES), potassium chloride (KCl), Protease
Inhibitor Cocktail, rifampicin, Sephadex G-25 DNA Grade column, sodium azide,
sodium bicarbonate (NaHCO3), sodium chloride (NaCl), sodium deoxycholate,
sodium dodecyl sulfate (SDS), sodium hydroxide (NaOH), triethylammonium
bicarbonate (TEAB), thioflavins S and T (ThS and ThT), trifluoroacetic acid (TFA),
Triton X-100, Trizma, Tween 20, and Trypan Blue were all purchased from Sigma-
Aldrich (St. Louis, MO). C18 Tips, Dead Cell Apoptosis kit (Alexa 488-conjugated
annexin V/propidium iodide (PI)), formic acid, G418 sulfate (Geneticin), Hoechst
33342, hydroxylamine, Lipofectamine LTX Reagent, Lurai-bertani (LB), NP40 Cell
Lysis Buffer Opti-MEM Reduced Serum Medium, Pierce BCA Protein Assay kit,
Pierce Trypsin/Lys-C Protease Mix and tandem mass tag (TMT)-labeling kit were
from Thermo Fisher Scientific (Waltham, MA). CellTiter 96 AQueous One Solu-
tion (MTS) Cell Proliferation Assay was purchased from Promega (Madison, WI).
Synthesis of oligopyridylamide-based protein mimetics. The protocols for
synthesis, fluorescent dye-labeling and characterization of the relevant oligopyr-
idylamides are presented in Supplementary Section 6. For each experiment, fresh
stocks of the oligopyridylamides (10 mM) were prepared in DMSO and filtered
using 0.22 μm Ultrafree-MC spin filters (Sigma).
Peptide preparation. Peptides (pWT, pR248W and ReACp53; sequences shown in
Fig. 1c) were synthesized by Selleck Chemicals (Houston, TX) using standard Fmoc
methods. The peptides were purified inhouse by reverse-phase high-performance
liquid chromatography (Waters 2535 QGM HPLC), and purity was subsequently
verified using mass spectrometry (Agilent 6538 QToF LC/MS). After purification,
peptides were aliquoted into 0.5 mL Protein LoBind tubes (Eppendorf), lyophilized
and stored at −80 °C until needed. For each experiment, fresh peptide stock
solutions were prepared in DMSO and filtered using 0.22 μm Ultrafree-MC spin
filters. pR248W concentration was determined by absorbance measurements at
280 nm (ε= 5690 cm–1 M–1 for tryptophan) on a Lambda 25 UV/Vis Spectro-
photometer (PerkinElmer, Waltham, MA) using quartz cuvettes (1 cm path-
length).
Thioflavin T (ThT)-based aggregation assay. Peptide (pWT and pR248W)
amyloid formation kinetics were measured in quadruplicate in black 96-well plates
with flat bottom (Corning Inc., NY) using a Synergy H1MF Multi-Mode micro-
plate reader controlled by Gen5 software (version 2.0; BioTek, Winooski, VT). The
aggregation was initiated by dilution of peptide from a freshly prepared stock
solution (1 mM in DMSO) to PBS containing ThT, with or without oligopyr-
idylamides. For some experiments, the oligopyridylamides were added (from a
stock solution of 10 mM in DMSO) at the indicated timepoint after the start of the
aggregation reaction. To maintain identical conditions, an equal amount of DMSO
was added to the wells with peptide only reactions. Final concentrations in the wells
were: 25 μM pWT or pR248W; 0 or 25 μM oligopyridylamide; 50 μM ThT. Peptide
aggregation was monitored by shaking and measuring the ThT fluorescence (λex/em
= 440/480 nm) at 5-min intervals at 37 °C. The sample data were processed by
subtracting the blank and renormalizing the fluorescence intensity by setting the
maximum value to one.
Transmission electron microscopy (TEM). Twenty-five micromoles of 25 μM
pR248W was incubated, alone or co-mixed with an equimolar concentration of
ADH-1, ADH-6, or ReACp53, for 10 h at 37 °C. Thereafter, the solution was
vortexed and a 5 μL droplet of the solution was placed on a freshly plasma-cleaned
copper/formvar/carbon grid (400 mesh, Ted Pella, Redding, CA). After 2 min, the
droplet was wicked away by carefully placing the grid perpendicularly on a filter
paper. The grid was then gently washed by dipping the upper surface in a water
droplet and dried as described above using a filter paper. Next, the grid was placed
upside down for 20 s in a 1% phosphotungstic acid (PTA) solution that had been
passed through a 0.2 μm filter and centrifuged at 24,000 × g for 10 min to remove
potential PTA agglomerates. The PTA solution was wicked away and the grid was
further dried for 10 min under cover at room temperature. Images of at least five
different grid regions were acquired per experimental condition on a Talos F200X
TEM (Thermo Fisher Scientific) equipped with a Ceta 16 M camera operated at an
accelerating voltage of 200 kV. Velox software (version 2.9.0; Thermo Fisher Sci-
entific) was used for image analysis.
Dot blot immunoassay. Samples of 10 μM pR248W, in the absence or presence of
an equimolar amount of the ligands (ADH-1 or ADH-6), were incubated for
various durations. The samples were then applied to a nitrocellulose membrane
and dried for 1 h at room temperature or overnight at 4 °C. The membranes were
subsequently blocked with 5% nonfat milk in TBST buffer (10 mM Tris, 0.15 M
NaCl, pH 7.4, supplemented with 0.1% Tween 20) for 2 h at room temperature,
washed thrice with TBST buffer, and incubated overnight at 4 °C with the poly-
clonal A11 antibody (AHB0052; Thermo Fisher Scientific) (1:1000 dilution in 5%
nonfat milk in TBST buffer). Next, the samples were washed with TBST buffer (×3)
and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
(ab6721; Abcam, Cambridge UK) secondary antibody (1:500 dilution in 5% nonfat
free milk in TBST buffer) for 1 h at room temperature. The dot blots were then
washed with TBST buffer (×5), developed using the ECL reagent kit (Amersham,
Piscataway, NJ), and finally imaged using a Typhoon FLA 9000 instrument (GE
Healthcare Life Sciences, Pittsburgh, PA) with the settings for chemiluminescence.
Circular dichroism (CD) spectroscopy. Each freshly prepared pR248W stock
solution was diluted in PBS to a concentration of 10 μM, alone or with an equi-
molar concentration of the ligand (ADH-1 or ADH-6), and transferred to a 1-mm
quartz cuvette. CD spectra were recorded from 190 to 260 nm, with a bandwidth of
0.5 nm, a step size of 0.5 nm, and a time-per-point of 10 s, at 25 °C using a
Chirascan Plus Circular Dichroism Spectrometer (Applied Photophysics Limited,
UK) with a Peltier temperature control system. For each experiment, the CD
spectra from three independent trials were averaged and baseline corrected.
Tryptophan fluorescence quenching assay. The binding interaction between the
oligopyridylamides (ADH-1 and ADH-6) and mutant pR248W was characterized
using a published steady-state intrinsic tryptophan fluorescence quenching
assay99,100. A 1 mM stock solution of pR248W was prepared in PBS. The peptide
solution was then diluted to a final concentration of 5 μM and equilibrated at 20 °C
for 5 min before commencing titration. Subsequently, the ligands (from a stock
concentration of 10 mM in DMSO) were serially added to the peptide solution,
which was stirred and allowed to equilibrate for 10 min before the intrinsic tryp-
tophan fluorescence was measured from 300 to 420 nm (λex= 280 nm) on a Cary
Eclipse Fluorescence Spectrophotometer (Agilent, Santa Clara, CA). The back-
ground corrections in fluorescence changes because of dilution effects with the
stepwise addition of ligands were made by buffer titrations. Curve fitting and the
analysis of the data were performed using Prism (version 8.4.2; GraphPad Software
Inc., La Jolla, CA, USA). All binding curves were fit to the one-site-specific binding
model to determine equilibrium dissociation constants (Kd):
Y ¼ Bmax ´X
Kd þ X
ð1Þ
where X is the final concentration of the ligand, Y is the percentage increase in
pR248W fluorescence quenching relative to the control fluorescence signal (i.e.
pR248W alone), and Bmax is the extrapolated maximum specific binding.
NMR spectroscopy. NMR samples were prepared with the DBDs of WT and
mutant R248W p53. The 15N-uniformly labeled proteins were expressed and
purified using published procedures37 by Giotto Biotech S.r.l. (Sesto Fiorentino,
Italy) and supplied as 1 mg/mL solutions in buffer (50 mM Tris, 200 mM KCl, 5
mM DTT (pH 7.5)). After mild concentration by ultracentrifugation and spec-
troscopic inspection, the original buffer was replaced by dialysis, first against 50
mM KH2PO4/K2HPO4, 150 mM KCl, 5 mM DTT (pH 6.8), and subsequently
against H2O with 5 mM DTT which resulted in final pH values of 5.6–5.8. The
protein concentrations were in the 40–50 μM range in Tris and phosphate buffers,
and in the 19–24 μM range in water, with 4–5% D2O always present. Additions of a
few microlitres of ADH-6 (from 5 or 24 mM stock solutions in H2O or a 200 mM
stock solution in DMSO) were performed to assess the protein–drug interaction.
NMR spectra were collected at 14.0 T (1H resonance at 600.19 MHz) on a
Bruker Avance III NMR system equipped with triple resonance cryoprobe. All the
spectra were acquired at 293.2 K. Two-dimensional 15N–1H HSQC experiments101
were executed using sensitivity-improved Echo/Antiecho-TPPI pure phase
detection in F1, gradient-based coherence selection and flip-back pulse for solvent
suppression102–104. To improve the resolution, the corresponding TROSY-based
experiments105,106 were also collected. All acquisitions were carried out over
spectral widths of 40 and 16 ppm in F1 and F2 dimensions, respectively, with 128
time-domain points in t1, 128–256 scans × 2048 points in t2 and 64 dummy scans
to achieve steady state. The NMR data were processed with TOPSPIN (version
4.0.2; Bruker). Prior to Fourier transformation, linear prediction in t1 (up to 256
points) and zero filling were applied to yield a final data set of 2K × 1K points. The
chemical shift variations (Δδ) of the protein peaks from 15N-1H HSQC spectra
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to properly account for both 1H (ΔδH) and 15N (ΔδN) frequency changes upon
ligand interaction.
Cell culture. Prior to use, all cell lines were authenticated and tested for myco-
plasma contamination by Charles River Laboratories (Margate, UK). The following
cell lines were purchased from American Type Culture Collection (ATCC; Man-
assas, VA): human bone (U-2 OS [ATCC no. HTB-96] and Saos-2 [HTB-85]),
brain (SH-SY5Y [CRL-2266]), breast (HCC70 [CRL-2315], MCF-7 [HTB-22],
MDA-MB-175-VII [HTB-25], MDA-MB-231 [HTB-26] and SK-BR-3 [HTB-30]),
colon (COLO 320DM [CCL-220], HT-29 [HTB-38], LS123 [CCL-255] and LS
174T [CL-188]), gastric (AGS [CRL-1739]), leukemia (ARH-77 [CRL-1621] and
CESS [TIB-190]), lung (A549 [CCL-185], NCI-H1770 [CRL-5893], NCI-H1882
[CRL-5903], NCI-H2342 [CRL-5941] and NCI-H748 [CRL-5841]), ovarian
(OVCAR-3 [HTB-161] and SKOV-3 [HTB-77]), pancreatic (MIA PaCa-2 [CRL-
1420]), and renal (CAKI-1 [HTB-46]), cancer cells. The cells were cultured in
medium (DMEM, RPMI 1640 or Ham′s Nutrient Mixture F12; Sigma) supple-
mented with 10% fetal bovine serum (FBS; GE Healthcare Life Sciences, Logan,
UT), 4 mM L-glutamine, 1 mM sodium pyruvate and 1% penicillin/streptomycin
(all from Sigma) in 5% CO2 at 37 °C, and viability was monitored regularly using
the Trypan Blue exclusion test on a TC20 automated cell counter (Bio-Rad, Her-
cules, CA). Once the cells reached ~95% confluence, they were split (using 0.25%
trypsin-EDTA; Sigma) into fractions and propagated or used in experiments.
ThS fluorescence imaging. The benzothiazole dye ThS was used to stain intra-
cellular mutant p53 aggregates39. MIA PaCa-2 cells were seeded at a density of 2 ×
104 cells/well in 500 μL complete DMEM in four-chambered 35 mm glass bottom
Cellview cell culture dishes (Greiner Bio-One, Monroe, NC). After culturing for 24
h, the medium was replaced by fresh medium containing 125 μM of ThS and
incubated for 1 h. Thereafter the medium was removed, the cells were washed, and
fresh DMEM containing 10 µM ADH-1, ADH-6, or ReACp53 was added and
incubated for 0.5–6 h. Finally, the medium was once again replaced with fresh
DMEM and the cells were imaged on an Olympus Fluoview FV-1000 confocal laser
scanning microscope, using a ×63 Plan-Apo/1.3 NA oil immersion objective with
DIC capability. Images were acquired using the FV10-ASW Viewer software
(version 4.2; Olympus) and analyzed using the Fiji image processing software
(ImageJ2 core with plugins for scientific image analysis; https://imagej.net/Fiji).
Immunofluorescence. MIA PaCa-2 and MCF-7 cells were seeded at a density of
2 × 104 cells/well in 500 μL complete DMEM in four-chambered 35 mm glass
bottom Cellview cell culture dishes and cultured for 24 h. Following treatment with
vehicle or 2.5–10 µM ADH-1, ReACp53, or ADH-6 (unlabeled or FITC-labeled,
ADH-6FITC) for 0.5 or 6 h, the cells were rinsed with ice-cold PBS, fixed with 4%
PFA, permeabilized with 0.5% Triton X-100, and blocked in 5% BSA. Subsequently,
the cells were incubated with 5 μg/ml p53 antibody (PAb 240, sc-99; Santa Cruz
Biotechnology, Dallas, TX), overnight at 4 °C, which was followed by incubation
with Alexa 488- or Alexa 594-labeled anti-mouse IgG (ab150117 or ab150120,
respectively; Abcam) secondary antibody (1:800 dilution) for 1 h at room tem-
perature. Finally, the cells were imaged on an Olympus Fluoview FV-1000 confocal
laser scanning microscope, and the images were analyzed using the Fiji image
processing software.
Cell fractionation and western blot analysis. Cell fractionation and western blot
were done using standard procedures107,108. Cells were washed with ice-cold PBS,
harvested by trypsinization, and centrifuged. The resulting cell pellet was lysed
using 100 μL lysis buffer (Bio-Rad), and lysis was confirmed by light microscopy.
For separation of the insoluble (pellet) and soluble (supernatant) fractions, the
whole-cell lysate was centrifuged (20,000 × g for 20 min at 4 °C), and the protein
content of the two fractions was determined using the bicinchoninic acid (BCA)
protein assay109.
Samples (20 µg/lane) were electrophoresed on a 4–12% sodium dodecyl sulfate
(SDS)-polyacrylamide gel in a Mini-PROTEAN Tetra Cell (Bio-Rad) and
subsequently transferred to a nitrocellulose membrane (Sartorius AG, Göttingen,
Germany), which was blocked with 5% nonfat milk and then incubated with p53
(DO-7, sc-47698; Santa Cruz), p21 (EPR3993, ab109199; Abcam), Noxa (114C307,
sc-56169; Santa Cruz), Bax (E63, ab32503; Abcam) or MDM2 (2A10, ab16895;
Abcam) antibodies (1:1000), or β-actin antibody (2A3, sc-517582; Santa Cruz)
(1:2000), overnight at 4 °C. This was followed by incubation for 3 h at room
temperature with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-
rabbit IgG (ab205719 or ab6721, respectively; Abcam) secondary antibody
(1:10,000). Finally, the samples were visualized using Clarity Western ECL
Substrate (Bio-Rad) on a Bio-Rad Gel Doc XR+ Gel Documentation System
(Image Lab software, version 4.1). For densitometric quantification, the
immunoblot bands were normalized to β-actin.
Cellular thermal shift assay (CETSA). CETSA experiments were performed
according to a published protocol43. MIA PaCa-2 or SK-BR-3 cells were treated
with vehicle or 5 μM ADH-1 or ADH-6. After incubation for 6 h, the cells were
washed with ice-cold PBS, harvested by trypsinization, centrifuged, and re-
suspended in PBS supplemented with complete Protease Inhibitor Cocktail. Equal
amounts of cell suspensions were aliquoted into 0.2 mL PCR microtubes and
incubated for 30 min at room temperature. Subsequently, the cell suspension ali-
quots were heated individually at the indicated temperatures for 3 min (Ristretto
Thermal Cycler; VWR, Darmstadt, Germany), followed by cooling for 3 min at on
ice. Finally, the cells were lysed using two cycles of freeze–thawing, and the soluble
fractions were isolated by centrifugation and analyzed by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by western blot as described above. Fold-
changes in the immunoblot band densities (normalized to the β-actin controls and
using the lowest temperature condition as reference) were plotted as a function of
temperature to generate mutant p53 melt curves for the different treatments. Curve
fitting and calculation of the melting point, i.e. the temperature at which half of the
protein amount has been denatured (Tm), were done using published
procedures43,44.
Plant cell studies
Plants and growth conditions. Nicotiana benthamiana were sown in soil and grown
at 24 °C (morning) and 22 °C (night) in a growth chamber under an 8 h-light/16 h-
dark cycle. After 2 weeks, the seedlings were transplanted into pots (one seedling
per pot) and grown for a further 5–6 weeks before conducting Agrobacterium
tumfaciens-mediated transient assays.
Plasmid construction. WT and mutant R248W p53 DBDs were cloned using the
Gateway system (Thermo Fisher Scientific). Genes for WT and R248W p53 DBDs
were respectively amplified from the vector pCMV-Neo-Bam carrying WT and
R248W p53 constructs (plasmids #16434 and #16437, respectively; Addgene,
Watertown, MA). Gene-specific primers for the p53 DBDs were designed to
incorporate the CACC tag at the 5′ end of both constructs. The following primers
were used for amplifying p53 DBDs: p53 forward, 5′-caccTCATCTTCTGTCCC
TTCCCAGAAAACC-3′; and p53 reverse, 5′-tcaGGGCAGCTCGTGGTGAGGC
TCCCCT-3′ (note that the underlined CACC tag in lowercase is not a part of the
p53 sequence) (Supplementary Table 1a). Phusion DNA Polymerase (New England
Biolabs) was used for the gene-specific amplification of the p53 DBD constructs.
The PCR amplified DNA constructs were subcloned in pENTR Directional TOPO
(D-TOPO) (Thermo Fisher Scientific). The gateway binary vectors pEarleyGate
101 (35S promoter, C:YFP) and pEarleyGate 104 (35S promoter, N:YFP) were used
as the destination vectors for the p53 DBD constructs. The WT p53 DBD was
cloned with a YFP tag at the N terminus and an amino acid sequence,
RVGAPTQLSCTKWC, at the C-terminal end that corresponds to the att site (5′-
aagggtgggcgcgccgacccagctttcttgtacaaagtggTGCTAG-3′). The R248W p53 DBD, also
cloned with a YFP tag at the N terminus, had a stop codon (TAA) at the C-
terminal end. (Note: the nucleotides in lowercase are the att sites, while the
uppercase nucleotides are part of the vector. The stop codon is underlined.) Since
the entry and destination vectors had the same antibiotic selection marker
(kanamycin), we followed the PCR amplification based (PAB) method110 to
recombine the DNA fragment from the entry vector into the destination vector.
The DNA fragment was amplified from the entry vector using M13 primers (M13
forward, 5′-GTAAAACGACGGCCAG-3′, and M13 reverse, 5′-CAGGAAA-
CAGCTATGAC-3′; Supplementary Table 1a) and was subsequently recombined
with the destination vector using LR Clonase (Thermo Fisher Scientific). The
plasmids were then transformed in Agrobacterium tumfaciens strain GV3101.
Agrobacterium-mediated transient expression. N. benthamiana leaves were infil-
trated with A. tumfaciens carrying the desired constructs using published
protocols111,112. A. tumfaciens strain GV3101 carrying the WT and mutant R248W
p53 DBDs were grown overnight at 28 °C in Lurai-bertani (LB) medium containing
the appropriate antibiotics (100 µg/mL kanamycin, 50 µg/mL gentamycin, or 100
µg/mL of rifampicin). Cells were re-suspended in induction media (10 mM MES,
pH 5.6, 10 mM MgCl2 and 200 µM acetosyringone) and incubated for 2 h at room
temperature before infiltration (at a final OD of 1.0) of N. benthamiana leaves.
Confocal microscopy analysis. Intracellular localization of YFP:p53DBDWT and
YFP:p53DBDR248W was observed at 72 h post infiltration (hpi). To determine the
effects of ADH-1, ReACp53, and ADH-6 on p53 DBD aggregation, at 48 hpi the
oligopyridylamides/peptide were diluted in 10 mM MgCl2 to a final concentration
of 5 µM and then infiltrated into the N. benthamiana leaves for 24 h. The leaves
from the infiltrated area were isolated and cells towards the abaxial side were
imaged on a NIKON Eclipse LV100 upright microscope, and the images were
analyzed using the Fiji image processing software.
Transfection of p53 null cancer cells with mutant p53. Human bone cancer
Saos-2 and ovarian cancer SKOV-3 cells were plated at a density of 1 × 105 cells/
well in 2 mL complete medium in six-well plates and cultured for 48 h. For each
well of cells to be transfected, 2.5 μg pCMV-Neo-Bam p53 R175H or pCMV-Neo-
Bam p53 R248W vectors (plasmids #16436 or #16437, respectively; Addgene)
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containing the ampr gene was diluted in 500 μL Opti-MEM Reduced Serum
Medium in an Eppendorf tube, to which 10 μL Lipofectamine LTX Reagent was
added, mixed gently, and incubated for 30 min at room temperature. The medium
in the wells was then replaced with the Opti-MEM Reduced Serum Medium
containing the DNA–Lipofectamine LTX Reagent complexes and the cells were
incubated in 5% CO2 at 37 °C for 24 h. Subsequently, the cells were harvested and
plated in T25 flasks (Corning). After culturing until ~95% confluence was reached,
the cells were selected with 400 μg/mL G418 sulfate-supplemented medium and
maintained thereafter in medium containing 100 μg/mL G418 sulfate.
To verify that the transfection was successful, the pCMV-Neo-Bam p53 R248W
and pCMV-Neo-Bam p53 R175H vectors containing the ampr gene were purified
from the transfected SKOV-3 and Saos-2 cells using the Qiaprep Miniprep Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The
miniprep-purified DNA samples were subsequently quantified using a NanoDrop
spectrophotometer. PCR was carried out to amplify the ampr genes using the
following primers: forward (5′-AGATTATCAAAAAGGATCTTCACCT-3′) and
reverse (5′-CCTCGTGATACGCCTATTTTTATAG-3′) (Integrated DNA
Technologies, Leuven, Belgium) (Supplementary Table 1b). Each PCR reaction
was prepared in 50 µL volume containing: 1 µL of each primer (0.2 µM final primer
concentration), 50 ng DNA, 25 µL Taq 2× PCR Master Mix (New England Biolabs,
Ipswich, MA), and nuclease-free water. The conditions for each PCR reaction were
initial denaturation at 95 °C for 30 s, 35 cycles of denaturation at 95 °C for 30 s,
annealing at 50 °C for 30 s, and extension at 68 °C for 1 min. As a negative control,
a PCR reaction was carried out with the same reagents sans DNA. The amplified
products were then resolved by electrophoresis using a 3% agarose gel prepared in
1× TAE (Tris/acetic acid/EDTA) buffer (Bio-Rad) containing GelGreen Nucleic
Acid Stain (Biotium, Freemont, CA), which was visualized on an E-Gel Imager
Blue-Light Base (Thermo Fisher Scientific). The presence of the successfully
amplified ampr PCR products was confirmed using a standard 500 bp ladder.
Cell viability/toxicity assays. Cell viability/toxicity was measured using two
complementary assays: (i) CellTiter 96 AQueous One Solution (MTS) assay, which
measures reduction of the tetrazolium compound MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) to
soluble formazan, by mitochondrial NAD(P)H-dependent dehydrogenase
enzymes, in living cells113,114 and (ii) Dead Cell Apoptosis assay, in which Alexa
488-conjugated annexin V is used as a sensitive probe for detecting exposed
phosphatidylserine in apoptotic cells115, and red-fluorescent propidium iodide (PI),
a membrane impermeant nucleic acid binding dye, assesses plasma membrane
integrity and distinguishes between apoptosis and necrosis116.
For the MTS assay, cells were seeded at densities of 5 × 103–2 × 104 cells/well in
100 μL complete medium in standard 96-well plates. After culturing for 24 h, the
medium was replaced with serum-free medium containing the oligopyridylamides
at the desired concentrations, and incubated for the indicated durations, at 37 °C.
Thereafter, the incubation medium was replaced with fresh complete medium, and
20 μL MTS reagent was added to each well and incubated for 2 h at 37 °C. Finally,
absorbance of the soluble formazan product (λ= 490 nm) of MTS reduction was
measured on a Synergy H1MF Multi-Mode microplate reader (BioTek), with a
reference wavelength of 650 nm to subtract background. Wells treated with vehicle
were used as control, and wells with medium alone served as a blank. MTS
reduction was determined from the ratio of the absorbance of the treated wells to
the control wells.
For the Dead Cell Apoptosis assay, MIA PaCa-2 cells were treated with 5 μM
ADH-1, ADH-6, or ReACp53 for 24 h at 37 °C. Subsequently, the cells were
washed with ice-cold PBS, harvested by trypsinization, centrifuged, and re-
suspended in 1× annexin-binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2, pH 7.4) to a density of ~1 × 106 cells/mL. The cells were then stained with 5
µL Alexa 488-conjugated annexin V and 0.1 µg PI per 100 µL of cell suspension for
15 min at room temperature. Immediately afterwards, fluorescence was measured
using flow cytometry (≥10,000 cells/sample) on a BD FACSAria III cell sorter (BD
Biosciences, San Jose, CA) controlled by BD FACSDiva software (version 8.0), and
the fractions of live (annexin V−/PI−), early and late apoptotic (annexin V+/PI−,
and annexin V+/PI+, respectively), and necrotic (annexin V−/PI+) cells were
determined using FlowJo (version 10.6; FlowJo LLC, Ashland, OR).
Cell cycle analysis. Cell cycle distribution was determined using flow
cytometry117,118. MIA PaCa-2 cells were seeded at a density of 1 × 106 cells/well in
1 mL complete DMEM. After culturing for 24 h, the medium was replaced with
serum-free DMEM containing 5 µM ADH-1, ReACp53, or ADH-6, and the cells
were incubated for 6 h. Subsequently, the cells were washed with PBS, harvested by
trypsinization, and centrifuged (800 × g for 5 min). The supernatant was discarded,
and the cells were washed with PBS and fixed in 70% cold ethanol overnight at
4 °C. The cells were then washed with PBS, filtered through a nylon sieve, and
centrifuged again (800 × g for 5 min), and the supernatant was discarded. The cells
were stained with Nuclear Green CCS1 (Abcam) for 30 min at 37 °C and data
(10,000 cells/sample) were collected on a BD FACSAria III cell sorter and subse-
quently analyzed using FlowJo.
Chromatin immunoprecipitation (ChIP) coupled with quantitative PCR (ChIP-
qPCR). MIA PaCa-2 cells were cultured in complete DMEM in T175 flasks
(Corning) until 70–80% confluence was reached. Thereafter, the medium was
replaced with serum-free DMEM containing vehicle or 5 µM ADH-6, and the cells
were incubated for a further 24 h. The cells were then treated with 1% PFA for 10
min at 37 °C for crosslinking, followed by a single wash with 5 mL PBS. In all, 1.5
mL buffer A (5 mM PIPES, pH 8, 85 mM KCl, 0.5% NP40, Protease Inhibitor
Cocktail) was added to the cells, which were harvested using a pipette tip and
scrapper. The cell suspension was rotated for 10 min at 4 °C, centrifuged (1700 × g
for 5 min at 4 °C), and the supernatant was discarded. To the cell pellet, 400 µL
buffer B (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) was added, and the cell
suspension was sonicated (10 cycles of 5 s each at maximum power, with 2 min on
ice between cycles to prevent overheating). Cell debris was removed by cen-
trifugation (21,000 × g for 10 min at 4 °C), and the supernatant was collected. The
samples were diluted tenfold with the immunoprecipitation buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCL, pH 8.1), rotated for 30 min
at room temperature, followed by centrifugation (300 × g for 20 s at 4 °C). Of the
collected supernatant, 100 µL was used as input for each sample, with the
remainder incubated with 1 µg/mL of the antibody for p53 (DO-1, sc-126; Santa
Cruz), p63 (D2K8X, #13109; Cell Signaling Technology, Danvers, MA), or p73
(EPR19884, ab215038; Abcam), overnight on a rotator at 4 °C. Fifty microliters
magnetic beads (Magna ChIP protein A+G bead blend; Sigma) was added to each
sample solution and rotated for 30 min at room temperature. After rotation, the
samples were incubated for 30 s on a magnetic stand to separate the chromatin,
which was then washed twice with wash buffer 1 (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris-HCL, pH 8.1, 150 mM NaCl), followed by twice with wash
buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL, pH 8.1, 300
mM NaCl), twice with wash buffer 3 (0.25 M LiCl, 1% NP40, 1% sodium deox-
ycholate, 1 mM EDTA, 10 mM Tris-HCL, pH 8.1), and finally once with TE buffer
(10 mM Tris-HCL, pH 8.1, 1 mM EDTA). Immediately after the washes, the
samples were eluted by adding the elution buffer (0.5% SDS, 5 mM EDTA, 25 mM
Tris-HCL, pH 7.5, 20 mM NaCl), followed by vortexing and incubation for 15 min
at 65 °C. Subsequently, the samples were incubated on a magnetic stand and 200 µL
supernatant was collected, to which 200 µL immunoprecipitation buffer was added,
followed by 1 µL Protease Inhibitor Cocktail, and the samples were incubated
overnight at 65 °C. DNA was recovered with a conventional inhouse DNA pre-
cipitation method using sodium acetate, with samples eluted in volumes of 20 µL.
Finally, the recovered DNA was amplified and quantified (for qPCR reaction: 1 µL
DNA from ChIP samples or input, 1 µL 2 mM primers (Supplementary Table 1c),
5 µL SYBr Green PCR Master Mix (Thermo Fisher Scientific), and 3 µL nuclease-
free water). PCR thermal reaction cycle included one cycle of 10 min at 95 °C and
39 cycles of 15 s at 95 °C followed by 45 s at 60 °C. Normalization of PCR reaction
was based on calculating the enrichment by comparing the threshold cycle number
(CT) for the input and ChIP samples.
RNA sequencing (RNA-Seq)
RNA isolation and purification. Total RNA was extracted from MIA PaCa-2 cells
(1 × 106 cells/ well) treated with vehicle (control (C), n= 3) or oligopyridylamides
(5 µM ADH-1 or ADH-6, n= 3) using a combination of both TriZol (Thermo Fisher
Scientific) and RNAeasy Mini Kit (Qiagen) with modification of the manufacturers’
protocol. Prior to extraction, cells were washed once with 1mL PBS, suspended in
1mL TriZol LS reagent and transferred to 1.5mL Lobind tubes (Eppendorf) along
with 0.2mL chloroform. The TriZol lysate and chloroform mix were vortexed and
centrifuged (18,000 × g at 4 °C) for 15min, forming three distinctive phases of DNA
(lower phase), protein (middle phase), and RNA (upper phase). The upper aqueous
phase (~400mL of RNA) was transferred to a new 1.5mL tube where an equivalent
volume of 70% ethanol was added and mixed. The mixture was further purified using
an RNAeasy mini spin column (Qiagen) according to the manufacturer’s protocol.
RNA concentrations were determined using a NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA).
RNA-Seq library preparation, sequencing, and processing. Total RNA quality was
estimated based on the RNA integrity number (RIN) using a BioAnalyzer 2100
(Agilent, Santa Clara, CA). RNA samples with a RIN > 8 were used for library
preparation. RNA-Seq libraries were prepared using an Illumina TruSeq Stranded
mRNA prep kit as per the manufacturer’s protocol. Samples were barcoded, mul-
tiplexed, and sequenced (100 bp pair-end) using a NextSeq 550 System (Illumina,
San Diego, CA). DESeq2 computational pipeline119 was used to estimate the raw
count reads aligned to the reference genome. Human reference genome (GRCh38/
hg38) from UC Santa Cruz Genome Browser (https://genome.ucsc.edu/) was uti-
lized as a reference genome120. Computations were run on a Linux based command
system on the NYU Abu Dhabi High Performance Computing (HPC) server
platform Dalma (https://wikis.nyu.edu/display/ADRC/Cluster+-+Dalma). Raw
data were processed, and count data were normalized (to log2 counts per million
reads (log2cpm)) or transformed (using variance-stabilizing transformation (VST)).
Bioinformatic and computational analysis. Correlation (i.e. PCA, distance den-
drogram) and expression (i.e. heatmaps, boxplots) analyses were generated either
via RNA-Seq START (Shiny Transcriptome Analysis Resource Tool) application
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(NYU Abu Dhabi Center of Genomic and Systems Biology (NYUAD-CGSB)
Bioinformatics Online Analysis and Visualization Portal (http://tsar.abudhabi.nyu.
edu/))121 or the JMP genomics software (version 9.1; https://www.jmp.com/en_us/
software/genomics-data-analysis-software.html). Significance was assessed by false
discovery rate (FDR) adjusted P-value (P-adj or q-value), which was obtained from
the hypergeometric P-value that was corrected for multiple hypothesis testing using
the Benjamin and Hochberg procedure122. For GO analysis, DEGs, based on
corrected statistical significance (P-adj < 0.05), were submitted to the Database for
Annotation, Visualization Integrated Discovery (DAVID) bioinformatics tool
(version 6.8; https://david.ncifcrf.gov/home.jsp)123 to determine characteristics
under the “biological processes” category. Enrichment term values were based on
statistical significance of P < 0.05, which were normalized to −log10(P-value). GO
analysis charts were prepared using Excel.
IPA, performed with Upstream Regulator Analysis module of Ingenuity
Pathway Analysis software (QIAGEN Inc., Redwood City, CA; https://
digitalinsights.qiagen.com), was used to identify TRs responsible for gene
dysregulation in ADH-6 vs ADH-1 and ADH-6 vs control comparisons. For each
TR, the q-value and z-score, along with the number of genes, was obtained. The
number of genes that showed a pattern consistent with a TR’s activated or
repressed status were plotted along with the z-score and −log10(q-value) in a 2D
plot generated in R. Gene set enrichment analysis (GSEA, version 2.2.3; http://
software.broadinstitute.org/gsea/) was performed using the variance-stabilized
counts obtained from DESeq2 analysis against the Molecular Signatures Database
(MSigDB; http://www.gsea-msigdb.org/gsea/msigdb/index.jsp)124,125 for
identification of hallmark signatures. The enrichment plots, along with normalized
enrichment scores and q-values, were obtained from GSEA and are shown on
each plot.
Quantitative proteomics
Protein extraction and preparation of digests. MIA PaCa-2 cells (1 × 106 cells/well)
were treated with vehicle or 5 µM ADH-1, ReACp53, or ADH-6 for 16 h, harvested,
centrifuged, and lysed by adding five cell-pellet volumes of lysis buffer (100 μL lysis
buffer for every 20 μL cell pellet). The cell lysate was centrifuged (16,000 × g for
10 min at 4 °C) and the supernatant was transferred to a 1.5 mL LoBind tube. The
protein content of the sample was determined using the BCA protein assay. An
aliquot (100 µg of protein per treatment) was diluted to a final volume of 100 µl
with 100 mM TEAB buffer. Thereafter, the proteins were reduced (10 mM DTT for
1 h at 55 °C), S-alkylated (25 mM IAA, 30 min in the dark) and precipitated by
adding six volumes (~600 µL) of pre-chilled (−20 °C) acetone for 16 h. The protein
pellet collected by centrifugation (8000 × g for 10 min at 4 °C), washed with pre-
chilled acetone, air dried, and re-suspended in 100 µL TEAB (100 mM). The
proteins were digested with 1:40 (w/w) MS-grade Pierce Trypsin/Lys-C Protease
Mix for 24 h at 37 °C126.
Phosphopeptide enrichment using titanium dioxide (TiO2). Protein digests were
dried using SpeedVac and re-suspended in 1 mL loading buffer (80% acetonitrile
(ACN), 5% TFA and 1M glycolic acid)127. TiO2 beads (0.6 mg per 100 µg peptide
solution) were added, mixed well, and placed on a shaker for 15 min at room
temperature. The solution was then table centrifuged to pellet the beads, which
were subsequently mixed with 100 µL loading buffer, transferred to LoBind tube
and table centrifuged. Thereafter, the beads were washed first with 100 µL wash
buffer 1 (80% ACN, 1% TFA) followed by 100 µL wash buffer 2 (20% ACN, 0.2%
TFA). The bead pellet, collected by table centrifugation, was dried using SpeedVac,
mixed with 50 µL alkaline solution (28% NH3 in H2O, Thermo Fisher Scientific),
and incubated for 15 min at room temperature for phosphopeptide elution. The
solution was table centrifuged and the eluate was passed over a C18 Tip to recover
the phosphopeptides. Finally, the C18 tip was washed with 20 µL of 30% ACN
solution, collected in the same tube, and dried using SpeedVac.
TMT labeling. The phosphopeptide enriched digests were re-suspended in 100 µL
TEAB (100 mM). A labeling kit was used according to the manufacturer’s protocol
for TMT labeling128. TMT10plex amine-reactive reagents (0.8 mg per vial) were re-
suspended in 41 μL anhydrous ACN and all 41 μL of each reagent was added to
each sample and mixed briefly. Reactions were allowed to proceed at room tem-
perature for 1 h, which were then quenched by addition of 8 μL of 5% hydro-
xylamine for 15 min. Subsequently, the samples were combined in equal amount
(1:1), transferred to a LoBind tube, and dried using SpeedVac. The TMT-labeled
peptide mixtures were desalted on an Isolute MFC18 cartridge (100 mg/3 mL;
Biotage, Charlotte, NC). Eluted peptides were fractionated into 5 equal aliquots,
dried, and re-suspended in 20 µL of 0.1% formic acid solution prior to liquid
chromatography with tandem mass spectrometry (LC-MS-MS).
LC-MS/MS of TMT-labeled peptides using MS2. Liquid chromatography was per-
formed on a fully automated EASY-nLC 1200 (Thermo Fisher Scientific) fitted with
a C18 column (PepMap RSLC, 75 μm inner diameter, 15 cm length; Thermo Fisher
Scientific), which was kept at a constant temperature of 40 °C. Mobile phases
consisted of 0.1% formic acid for solvent A and 0.1% formic acid in ACN for
solvent B. Samples were loaded in solvent A, and a linear gradient was set as
follows: 0–5% B for 5 min, followed by a gradient up to 30% B in 50 min and
to 60% B in 65 min. A 10-min wash at 95% B was used to prevent carryover, and a
15-min equilibration with 0% B completed the gradient. The liquid chromato-
graphy system was coupled to a Q Exactive HF Hybrid Quadrupole-Orbitrap
(Thermo Fisher Scientific) equipped with an Easy-Spray Ion Source and operated
in positive ion mode. The spray voltage was set to 1.7 kV, S-lens RF level to 35, and
ion transfer tube to 275 °C. The full scans were acquired in the Orbitrap mass
analyzer that covered an m/z range of 350–1500 at a resolution of 120,000. The
automatic gain control (AGC) target was set to 3E6 and maximum ion time to
50 ms. The MS2 analysis was performed under data-dependent mode to fragment
the top 15 most intense precursors using higher-energy collisional dissociation
(HCD) fragmentation. The MS2 parameters were set as follows: resolution, 60,000;
AGC target, 1E5; minimum AGC target, 8.0E3; intensity threshold, 8.0E4; max-
imum ion time, 100 ms; isolation width, 1.2m/z; precursor charge state, 2–7;
peptide match, preferred; dynamic exclusion, 30 s; and fixed first mass, 100m/z.
The normalized collision energy for HCD was set to 32%.
Relative protein quantification using TMT. Relative protein abundances in the
different treatment groups were determined using PEAKS Studio proteomics
software (version 10.0, build 20190129; https://www.bioinfor.com//) with the fol-
lowing settings129: enzyme, trypsin; instrument, Orbitrap; fragmentation, HCD;
acquisition, data-dependent acquisition (DDA) without merging the scans; and
precursor and fragment mass tolerance, 20 ppm and 0.5 Da, respectively. The
correct precursor was detected using mass only. All peptide identifications were
performed within PEAKS using the UniProtKB_TrEMBL database with human
taxonomy (https://www.uniprot.org/uniprot). PEAKS PTM search tool was used to
find peptides with fixed (carbamidomethylation and TMT10plex) and variable
(phosphorylation (STY), oxidation (M) and deamidation (NQ)) modifications.
SPIDER search tool was used to find novel peptides that were homologous to
peptides in the protein database. The maximum number of variable posttransla-
tional modifications per peptide was 5, and the number of de novo dependencies
was 18. The de novo score threshold for SPIDER was 15, and the peptide hit score
threshold was 30. FDR threshold was set to 1%. Reporter ion quantification with
TMT-10plex (CID/HCD) was used. PEAKS was allowed to autodetect the reference
sample and automatically align the sample runs. Reporter ion intensity ≥1E4,
significance ≥16, fold change ≥1 and 2 unique peptides per protein were used to
filter the quantified protein lists.
Further subgroup analysis of differentially expressed phosphoproteins for
ADH-6 vs ADH-1 and ReACp53 vs ADH-1 was done by t-test for each group, and
only those proteins that differed significantly (P < 0.05) were considered
subsequently. Fold change of protein expression was obtained from the averaged
intensity value for each protein in ADH-6/ADH-1 or ReACp53/ADH-1.
Principal component and pathway analyses. PCA was performed to analyze the
main source of variation within and amongst the different treatment groups. Raw
counts were used for differently abundant proteins and were plotted using the
ClustVis application130. GSEA was performed for the “compute overlap function”
using MSigDB to identify hallmark signatures. For this analysis, the protein
accession IDs were converted to gene symbols using David Gene ID conversion
tool131. Significance was assessed by q-value (i.e. FDR-adjusted P-value)122, and the
data were ordered based on −log10(q-values).
Plots and network plots. Heatmaps showing differentially expressed phosphopro-
teins were generated in R using the Pearson correlation analysis132. GO-Chord plot
showing the pathways and the corresponding proteins that are part of each
pathway/gene signature was also generated in R. Biological roles of the phospho-
proteins in cancer were further inferred from published data (Supplementary
Table 2). Upregulated phosphoproteins were depicted using the PPI network map
generated via the search tool for retrieval of interacting genes (STRING)133.
In vivo tumor inhibition studies. All animal experiments were approved by the
NYU Abu Dhabi Institutional Animal Care and Use Committee (NYUAD-IACUC;
Protocol No. 18-0001), and were carried out in accordance with the Guide for Care
and Use of Laboratory Animals134. Athymic nude NU/J mice (Foxn1nu) were
purchased from The Jackson Laboratory (Bar Harbor, ME) and housed at the NYU
Abu Dhabi Vivarium Facility. Mice were maintained in air-filtered cages with
controlled temperature (20 °C) and humidity (50%), in a 12 h light/dark cycle, and
fed standard mouse chow (Research Diets; New Brunswick, NJ).
For pharmacokinetics, tumor-bearing mice (tumor volume ~25 mm3) were
randomly assigned to saline and ADH-6 treatment groups. A single dose of saline
or ADH-6 (15 mg kg-1) was administered via IP injection. Mice (n= 5–6 per
timepoint) were sacrificed at 0.5, 1, 2, 4, 8, 16, 24, 48, and 72 h following injection.
The blood was collected via terminal cardiac puncture using K3-EDTA as an
anticoagulant under isoflurane anesthesia and processed for plasma by
centrifugation (1500 × g for 5 min). Plasma and tissues were placed in
cryopreservation vials, preserved by snap freezing using liquid N2, and stored at
−80 °C until analysis by LC-MS/MS, which was performed according to a
published protocol135. ADH-6 stock solutions (1.0 mg/mL) were prepared in
acetonitrile (ACN). The matrix for the standard curve and quality controls (QC)
consisted of control mouse plasma for all plasma samples, or control tissue
homogenate for the tissue being analyzed. ADH-6 was extracted from 50 μL
standard, QC, or unknown sample by protein precipitation with 200 μL ACN/0.1%
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formic acid containing 20 ng/mL ADH-6 internal standard. Samples were vortexed
for 5 min, then centrifuged at 5000 × g for 10 min at 4 °C. Subsequently, 150 µL
supernatant was transferred to a clean 1.5 mL tube, lyophilized under N2, and
reconstituted in 60 μL ACN/0.1% formic acid. Fifty microliters of this was
transferred to a salinized glass 96-well plate insert containing 50 μL ddH2O and 10
μL of the sample was injected for analysis by LC-MS/MS.
For the single (mutant p53-harboring) xenograft inhibition studies, 5 × 105
viable MIA PaCa-2 or SK-BR-3 cancer cells were injected subcutaneously into the
right flank of each mouse at age 6–8 weeks. For the dual (WT and mutant p53-
bearing) xenograft model, 5 × 105 viable MIA PaCa-2 and MCF-7 cancer cells were
injected into the right and left flanks, respectively, of each mouse at age 6–8 weeks.
Mice were assessed daily for overt signs of toxicity. Tumor volume was determined
by high-precision calipers (Thermo Fisher Scientific) using the following formula:
tumor volume mm3




where W and L are tumor width and length in mm, respectively136. Mice were
euthanized once tumor volume approached burden defined by NYUAD-IACUC.
Once the tumor volume reached ~25 mm3, the mice were randomized into four
treatment groups (n= 8 per group), which were injected intraperitoneally with:
vehicle or the indicated concentrations of ADH-1, ReACp53, or ADH-6. Injections
were done every 2 days for a total of 12 doses, with the first day of treatment
defined as day 0. Body weight and tumor volume were recorded for the duration of
treatment, and survival (n= 4 per group) was monitored for a total of 30–60 days.
At the end of treatment, four mice per treatment group were sacrificed and the
tumor tissues were isolated to determine the tumor mass.
Isolated tumors and vital organs were formalin-fixed and paraffin-embedded
and sectioned into 7-μm slices. For hematoxylin and eosin (H&E) analysis, the
tissue sections were dewaxed and stained using standard procedures73. For IHC
analysis, the samples were prepared according to a published protocol14. The tissue
sections were treated by heat-induced epitope retrieval in 10 mM citrate buffer (pH
6.0) for antigen recovery, blocked with 8% BSA, then incubated overnight at 4 °C in
primary antibodies (1:400 DO-7 or 5 μg/mL PAb 240). This was followed by
sequential 45 min incubations at room temperature in biotinylated secondary
antibody and streptavidin-horseradish peroxidase (Abcam). Finally, the signal was
visualized upon incubation with the 3,3′-diaminobenzidine (DAB; Thermo Fisher
Scientific) substrate. The tissue sections were imaged on a NIKON LV100 upright
microscope and processed using the ECLIPSE LV software.
Statistics and reproducibility. For in vitro studies, investigators were blinded for
all parts of the experiments (treatment, data acquisition, and data analysis), and a
different investigator carried out each part. For in vivo studies, power calculation
was used to select sample sizes from the NYU Abu Dhabi Institutional Animal
Care and Use Committee (NYUAD-IACUC) Protocol (Protocol No. 18-0001), and
investigators were blinded for data acquisition and data analysis. Unless otherwise
indicated, error bars represent the mean ± standard deviation of at least three
biological replicates (i.e. n ≥ 3). Statistical analysis was performed using Prism
(version 8.4.2; GraphPad Software Inc., La Jolla, CA, USA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNA-Seq data have been deposited in the Gene Expression Omnibus (GEO) repository
(accession code: GSE161952) at the National Center for Biotechnology Information
(NCBI). Proteomics data have been deposited in the MassIVE repository (accession code:
MSV000086563; https://doi.org/10.25345/C5X78B) at the ProteomeXchange
Consortium. The following publicly available databases were used in the study: IARC
TP53 database (https://p53.iarc.fr), Database for Annotation, Visualization Integrated
Discovery (DAVID; https://david.ncifcrf.gov/home.jsp), Molecular Signatures Database
(MSigDB; http://www.gsea-msigdb.org/gsea/msigdb/index.jsp), and
UniProtKB_TrEMBL database (https://www.uniprot.org/uniprot). All the datasets
generated and/or analyzed during the current study are also available from the
corresponding authors on reasonable request. Source data are provided with this paper.
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